<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="312f1b5f-bfbc-7393-e063-6394a90adf08"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use TEMOZOLOMIDE CAPSULES safely and effectively.
 <br/>
See full prescribing information for TEMOZOLOMIDE CAPSULES.
 <br/>
TEMOZOLOMIDE capsules, USP, for oral use
 <br/>
Initial U.S. Approval: 1999
</title>
   <effectiveTime value="20250401"/>
   <setId root="5543dadb-9812-43d9-a899-ef875b9b1558"/>
   <versionNumber value="3"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="078779322"/>
            <name>NextSource Biotechnology LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="989968644"/>
                        <name>Eirgen Pharma Ltd.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="58181-4321" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="58181-4331" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="58181-4341" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="58181-4351" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="3143b16a-cc65-8e57-e063-6394a90a73ab"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250401"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="58181-4331" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Temozolomide</name>
                        <formCode code="C25158" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Temozolomide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3SY5LH9PMK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ANHYDROUS LACTOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H8AV0SQX4D" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="W4888I119H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TARTARIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4ELV7Z65AP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STEARIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SHELLAC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3K9958V90M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEHYDRATED ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ND2M416302" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ISOPROPYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="8PJ61P6TS3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BUTYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5138Q19F1X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMMONIA</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="L06K8R7DQK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 2</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="140"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="YF1K15M17Y" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TEMOZOLOMIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="YF1K15M17Y" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TEMOZOLOMIDE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43200" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POUCH"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="14" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="58181-4331-4" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250401"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA203898" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250401"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48333" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="blue" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="22" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">NSP;140mg</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="58181-4321" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Temozolomide</name>
                        <formCode code="C25158" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Temozolomide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3SY5LH9PMK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ANHYDROUS LACTOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H8AV0SQX4D" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="W4888I119H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TARTARIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4ELV7Z65AP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STEARIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SHELLAC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3K9958V90M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEHYDRATED ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ND2M416302" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ISOPROPYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="8PJ61P6TS3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BUTYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5138Q19F1X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMMONIA</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="L06K8R7DQK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 2</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1K09F3G675" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE RED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="100"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="YF1K15M17Y" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TEMOZOLOMIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="YF1K15M17Y" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TEMOZOLOMIDE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43200" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POUCH"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="14" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="58181-4321-4" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250401"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA203898" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250401"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48327" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="purple" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="20" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">NSP;100mg</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="58181-4341" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Temozolomide</name>
                        <formCode code="C25158" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Temozolomide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3SY5LH9PMK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ANHYDROUS LACTOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H8AV0SQX4D" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="W4888I119H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TARTARIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4ELV7Z65AP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STEARIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SHELLAC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3K9958V90M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEHYDRATED ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ND2M416302" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ISOPROPYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="8PJ61P6TS3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BUTYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5138Q19F1X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMMONIA</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1K09F3G675" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE RED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="180"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="YF1K15M17Y" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TEMOZOLOMIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="YF1K15M17Y" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TEMOZOLOMIDE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43200" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POUCH"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="14" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="58181-4341-4" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250401"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA203898" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250401"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48331" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="orange" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="22" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">NSP;180mg</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="58181-4351" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Temozolomide</name>
                        <formCode code="C25158" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Temozolomide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3SY5LH9PMK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ANHYDROUS LACTOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H8AV0SQX4D" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="W4888I119H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TARTARIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4ELV7Z65AP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STEARIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SHELLAC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3K9958V90M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEHYDRATED ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ND2M416302" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ISOPROPYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="8PJ61P6TS3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BUTYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5138Q19F1X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMMONIA</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="250"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="YF1K15M17Y" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TEMOZOLOMIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="YF1K15M17Y" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TEMOZOLOMIDE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43200" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POUCH"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="5" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="58181-4351-4" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250401"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA203898" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250401"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="22" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">NSP;250mg</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="L8cf0a947-f3b2-4524-87f3-f5b25de49e0d">
               <id root="3141e56c-fbba-7322-e063-6294a90a2234"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20250401"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%">
                           <caption/>
                           <tbody>
                              <tr>
                                 <td> Indications and Usage ( 
       <linkHtml href="#L925f30a2-4916-4730-8101-f3fc1c1f50f0">1.2</linkHtml>)
      </td>
                                 <td align="right"> 9/2023</td>
                              </tr>
                              <tr>
                                 <td> Dosage and Administration ( 
       <linkHtml href="#L631abb25-b00d-4d7c-8bd3-52c0d3f941c7">2.1</linkHtml>, 
       <linkHtml href="#La4f70f90-3a94-40d6-a5d6-e2b7490103eb">2.2</linkHtml>, 
       <linkHtml href="#Lc2b2d7b3-3bfe-4eae-9279-ee145c4d4a9e">2.3</linkHtml>, 
       <linkHtml href="#L381f182c-fb0e-424b-b09b-0ccda9913f01">2.4</linkHtml>)
      </td>
                                 <td align="right"> 9/2023</td>
                              </tr>
                              <tr>
                                 <td> Contraindications ( 
       <linkHtml href="#L77aedc9a-7d18-4259-9fc3-e0c552b06b0b">4</linkHtml>)
      </td>
                                 <td align="right"> 9/2023</td>
                              </tr>
                              <tr>
                                 <td> Warnings and Precautions ( 
       <linkHtml href="#L2b03d759-1023-43fd-90bb-52951c3e166d">5.1</linkHtml>, 
       <linkHtml href="#L62e6fbd2-9596-410f-b58c-dd99c18af3fb">5.2</linkHtml>, 
       <linkHtml href="#L518de09b-418e-4e71-8164-f9f9e863953a">5.4</linkHtml>, 
       <linkHtml href="#L645662c6-fdf7-4b2b-85e6-1b88efd90758">5.5</linkHtml>, 
       <linkHtml href="#Lfc481618-194c-44e0-8d83-04a6e3182934">5.6</linkHtml>)
      </td>
                                 <td align="right"> 9/2023</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Le4f5d063-3a53-492d-b3a6-36b75d799fa0">
               <id root="3141dd9d-95c9-caf1-e063-6394a90af128"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20250401"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Temozolomide is an alkylating drug indicated for the treatment of adults with:</paragraph>
                        <list listType="unordered">
                           <item>Newly diagnosed glioblastoma concomitantly with radiotherapy and then as maintenance treatment. ( 
     <linkHtml href="#Lfd2c0dcc-acf1-4150-aa57-b2c9b306e256">1.1</linkHtml>)
    </item>
                           <item>Anaplastic astrocytoma. ( 
     <linkHtml href="#L925f30a2-4916-4730-8101-f3fc1c1f50f0">1.2</linkHtml>)
	
     <list listType="unordered">
                                 <item>Adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma. ( 
       <linkHtml href="#L925f30a2-4916-4730-8101-f3fc1c1f50f0">1.2</linkHtml>)
      </item>
                                 <item>Treatment of adults with refractory anaplastic astrocytoma. ( 
       <linkHtml href="#L925f30a2-4916-4730-8101-f3fc1c1f50f0">1.2</linkHtml>)
      </item>
                              </list>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Lfd2c0dcc-acf1-4150-aa57-b2c9b306e256">
                     <id root="312f1b5f-bfbf-7393-e063-6394a90adf08"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1 Newly Diagnosed Glioblastoma</title>
                     <text>
                        <paragraph>Temozolomide Capsules are indicated for the treatment of adults with newly diagnosed glioblastoma, concomitantly with radiotherapy and then as maintenance treatment.</paragraph>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
               <component>
                  <section ID="L925f30a2-4916-4730-8101-f3fc1c1f50f0">
                     <id root="312f1b5f-bfc0-7393-e063-6394a90adf08"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2 Anaplastic Astrocytoma</title>
                     <text>
                        <paragraph>Temozolomide capsules are indicated for the:</paragraph>
                        <list listType="unordered">
                           <item>adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma;</item>
                           <item>treatment of adults with refractory anaplastic astrocytoma.</item>
                        </list>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="L395a7a0b-2d95-4f46-982b-77388096edc1">
               <id root="3141e77a-4926-8b07-e063-6294a90a5c37"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text/>
               <effectiveTime value="20250401"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <content styleCode="underline">Newly Diagnosed Glioblastoma</content>:
	
     <list listType="unordered">
                                 <item>75 mg/m 
       <sup>2</sup>once daily for 42 to 49 days concomitant with focal radiotherapy followed by initial maintenance dose of 150 mg/m 
       <sup>2</sup>once daily for Days 1 to 5 of each 28-day cycle for 6 cycles. May increase maintenance dose to 200 mg/ m 
       <sup>2</sup>for Cycles 2 to 6 based on toxicity. ( 
       <linkHtml href="#L631abb25-b00d-4d7c-8bd3-52c0d3f941c7">2.1</linkHtml>)
      </item>
                                 <item>Provide 
       <content styleCode="italics">Pneumocystis</content>pneumonia (PCP) prophylaxis during concomitant phase and continue in patients who develop lymphopenia until resolution to grade 1 or less. ( 
       <linkHtml href="#L631abb25-b00d-4d7c-8bd3-52c0d3f941c7">2.1</linkHtml>)
      </item>
                              </list>
                           </item>
                        </list>
                        <list listType="unordered">
                           <item>
                              <content styleCode="underline">Adjuvant Treatment of Newly Diagnosed Anaplastic Astrocytoma:</content>Beginning 4 weeks after the end of radiotherapy, administer Temozolomide orally in a single dose on days 1-5 of a 28-day cycle for 12 cycles. The recommended dosage for cycle 1 is 150 mg/ m 
     <sup>2</sup>per day and for Cycles 2 to 12 is 200 mg/ m 
     <sup>2</sup>if patient experienced no or minimal toxicity in Cycle 1. ( 
     <linkHtml href="#La4f70f90-3a94-40d6-a5d6-e2b7490103eb">2.2</linkHtml>)
    </item>
                           <item>
                              <content styleCode="underline">Refractory Anaplastic Astrocytoma:</content>Initial dose 150 mg/ m 
     <sup>2</sup>once daily on Days 1 to 5 of each 28-day cycle. ( 
     <linkHtml href="#La4f70f90-3a94-40d6-a5d6-e2b7490103eb">2.2</linkHtml>)
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="L631abb25-b00d-4d7c-8bd3-52c0d3f941c7">
                     <id root="31419a5b-4116-b0f2-e063-6294a90a3542"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Monitoring to Inform Dosage and Administration</title>
                     <text>
                        <paragraph>Prior to dosing, withhold Temozolomide until patients have an absolute neutrophil count (ANC) of 1.5 x 10
  <sup>9</sup>/L or greater and a platelet count of 100 x 10
  <sup>9</sup>/L or greater.
 </paragraph>
                        <paragraph>For concomitant radiotherapy, obtain a complete blood count prior to initiation of treatment and weekly during treatment.</paragraph>
                        <paragraph>For the 28-day treatment cycles, obtain a complete blood count prior to treatment on Day 1 and on Day 22 of each cycle. Perform complete blood counts weekly until recovery if the ANC falls below 1.5 x 10
  <sup>9</sup>/L and the platelet count falls below 100 x 10
  <sup>9</sup>/L.
 </paragraph>
                        <paragraph>For concomitant use with focal radiotherapy, obtain a complete blood count weekly and as clinically indicated.</paragraph>
                     </text>
                     <effectiveTime value="20240804"/>
                  </section>
               </component>
               <component>
                  <section ID="La4f70f90-3a94-40d6-a5d6-e2b7490103eb">
                     <id root="31419159-7330-b0f7-e063-6294a90a7e7c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Recommended Dosage and Dosage Modifications for Newly Diagnosed Glioblastoma</title>
                     <text>
                        <paragraph>Administer Temozolomide once daily for 42 to 49 consecutive days during the concomitant use phase with focal radiotherapy and then once daily on Days 1 to 5 of each 28-day cycle for 6 cycles during the maintenance use phase.</paragraph>
                        <paragraph>Provide 
  <content styleCode="italics">Pneumocystis</content>pneumonia (PCP) prophylaxis during the concomitant use phase and continue in patients who develop lymphopenia until resolution to Grade 1 or less 
  <content styleCode="italics">[see Warnings and Precautions ( 
   <linkHtml href="#L0ea5877a-44fb-4c11-8b4f-e81641c0216d">5.3</linkHtml>)] 
  </content>.
 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Concomitant Use Phase:</content>
                        </paragraph>
                        <paragraph>The recommended dosage of Temozolomide is 75 mg/ m 
  <sup>2</sup>once daily for 42 days to 49 days in combination with focal radiotherapy. Focal radiotherapy includes the tumor bed or resection site with a 2 to 3 cm margin.
 </paragraph>
                        <paragraph>Other administration schedules have been used.</paragraph>
                        <paragraph>Obtain a complete blood count weekly. The recommended dosage modifications due to adverse reactions during concomitant use phase are provided in 
  <content styleCode="bold">Table 1</content>.
 </paragraph>
                        <paragraph/>
                        <table width="100%">
                           <caption> TABLE 1: Dosage Modifications Due to Adverse Reactions During Concomitant Use Phase</caption>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <content styleCode="bold">Adverse Reaction</content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <content styleCode="bold">Interruption</content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <content styleCode="bold">Discontinuation</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <content styleCode="bold">Absolute Neutrophil Count</content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">Withhold Temozolomide if ANC is greater than or equal to 0.5 × 10 
     <sup>9</sup>/L and less than 1.5 × 10 
     <sup>9</sup>/L. Resume Temozolomide at the same dose when ANC is greater than or equal to 1.5 × 10 
     <sup>9</sup>/L.
    </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">Discontinue Temozolomide if ANC is less than 0.5 × 10 
     <sup>9</sup>/L.
    </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <content styleCode="bold">Platelet Count</content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">Withhold Temozolomide if platelet count is greater than or equal to 10 × 10 
     <sup>9</sup>/L and less than 100 × 10 
     <sup>9</sup>/L.
     <br/>
			Resume Temozolomide at the same dose when platelet count is greater than or equal to 100 × 10 
     <sup>9</sup>/L.
    </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">Discontinue Temozolomide if platelet count is less than 10 × 10 
     <sup>9</sup>/L.
    </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <content styleCode="bold">Non-hematological Adverse Reaction (except for alopecia, nausea, vomiting)</content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">Withhold Temozolomide if Grade 2 adverse reaction occurs.
     <br/>
			Resume Temozolomide at the same dose when resolution to Grade 1 or less.
    </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">Discontinue Temozolomide if Grade 3 or 4 adverse reaction occurs.</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Single Agent Maintenance Use Phase:</content>
                        </paragraph>
                        <paragraph>Beginning 4 weeks after concomitant use phase completion, administer Temozolomide once daily on Days 1 to 5 of each 28-day cycle for 6 cycles. The recommended dosage of Temozolomide in the maintenance use phase is:</paragraph>
                        <list listType="unordered">
                           <item>Cycle 1: 150 mg/ m
   <sup>2 </sup>per day on days 1 to 5.
  </item>
                           <item>Cycles 2 to 6: May increase to 200 mg/m
   <sup>2 </sup>per day on days 1 to 5 before starting Cycle 2 if no dosage interruptions or discontinuation are required (Table 1). If the dose is not escalated at the onset of Cycle 2, 
   <content styleCode="bold">do not</content>increase the dose for Cycles 3 to 6.
  </item>
                        </list>
                        <paragraph>Obtain a complete blood count on Day 22 and then weekly until the ANC is above 1.5 x 10 
  <sup>9</sup>/L and the platelet count is above 100 x 10 
  <sup>9</sup>/L. Do not start the next cycle until the ANC and platelet count exceed these levels.
 </paragraph>
                        <paragraph>The recommended dosage modifications due to adverse reactions during the the maintenance use phase are provided in 
  <content styleCode="bold">Table 2</content>.
 </paragraph>
                        <paragraph>If Temozolomide is withheld, reduce the dose for the next cycle by 50 mg/m
  <sup>2 </sup>per day. Permanently discontinue Temozolomide in patients who are unable to tolerate a dose of 100 mg/m
  <sup>2 </sup>per day.
 </paragraph>
                        <table width="100%">
                           <caption> TABLE 2: Dosage Modifications Due to Adverse Reactions During Maintenance and Adjuvant Treatment</caption>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <content styleCode="bold">Adverse Reactions</content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <content styleCode="bold">Interruption and Dose Reduction</content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <content styleCode="bold">Discontinuation</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <content styleCode="bold">Absolute Neutrophil Count</content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">Withhold Temozolomide if ANC less than 1 × 10 
     <sup>9</sup>/L.
			
     <paragraph/>
                                    <paragraph>When ANC is above 1.5 × 10 
      <sup>9</sup>/L, resume Temozolomide at reduced dose for the next cycle.
     </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">Discontinue Temozolomide if unable to tolerate a dose of 100 mg/m
     <sup>2 </sup>per day.
    </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <content styleCode="bold">Platelet Count</content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">Withhold Temozolomide if platelet less than 50 × 10 
     <sup>9</sup>/L.
			
     <paragraph/>
                                    <paragraph>When platelet count is above 100 × 10 
      <sup>9</sup>/L, resume Temozolomide at reduced dose for the next cycle.
     </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">Discontinue Temozolomide if unable to tolerate a dose of 100 mg/m
     <sup>2 </sup>per day.
    </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <content styleCode="bold">Nonhematological Adverse Reactions (except for alopecia, nausea, vomiting)</content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">Withhold Temozolomide if Grade 3 adverse reaction occurs.
			
     <paragraph/>
                                    <paragraph>When resolved to Grade 1 or less, resume Temozolomide at reduced dose for the next cycle.</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">Discontinue Temozolomide if recurrent Grade 3 adverse reaction occurs after dose reduction, if Grade 4 adverse reaction occurs, or if unable to tolerate a dose of 100 mg/m
     <sup>2 </sup>per day.
    </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20240802"/>
                  </section>
               </component>
               <component>
                  <section ID="Lc2b2d7b3-3bfe-4eae-9279-ee145c4d4a9e">
                     <id root="31419a5b-4115-b0f2-e063-6294a90a3542"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Recommended Dosage and Dosage Modifications for Anaplastic Astrocytoma</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Adjuvant Treatment of Newly Diagnosed Anaplastic Astrocytoma</content>
                        </paragraph>
                        <paragraph>Beginning 4 weeks after the end of radiotherapy, administer Temozolomide orally in a single dose on days 1 to 5 of a 28-day cycle for 12 cycles. The recommended dosage of Temozolomide is:</paragraph>
                        <list listType="unordered">
                           <item>Cycle 1: 150 mg/m
   <sup>2 </sup>per day on days 1 to 5.
  </item>
                           <item>Cycles 2 to 12: 200 mg/m
   <sup>2 </sup>per day on days 1 to 5 if patient experienced no or minimal toxicity in Cycle 1. If the dose was not escalated at the onset of Cycle 2, 
   <content styleCode="bold">do not</content>increase the dose during Cycles 3 to 6.
  </item>
                        </list>
                        <paragraph>The recommended complete blood count testing and dosage modifications due to adverse reactions during adjuvant treatment are provided above and in Table 2 
  <content styleCode="italics">[see Dosage and Administration ( 
   <linkHtml href="#La4f70f90-3a94-40d6-a5d6-e2b7490103eb">2.2</linkHtml>)] 
  </content>.
 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Refractory Anaplastic Astrocytoma</content>
                        </paragraph>
                        <paragraph>The recommended initial dosage of Temozolomide is 150 mg/m 
  <sup>2</sup>once daily on Days 1 to 5 of each 28-day cycle. Increase the Temozolomide dose to 200 mg/m
  <sup>2 </sup>per day if the following conditions are met at the nadir and on Day 1 of the next cycle:
 </paragraph>
                        <list listType="unordered">
                           <item>ANC is greater than or equal to 1.5 x 10
   <sup>9</sup>/L and
  </item>
                           <item>Platelet count is greater than or equal to 100 x 10
   <sup>9</sup>/L.
  </item>
                        </list>
                        <paragraph>Continue Temozolomide until disease progression or unacceptable toxicity.</paragraph>
                        <paragraph>Obtain a complete blood count on Day 22 and then weekly until the ANC is above 1.5 x 10
  <sup>9</sup>/L and the platelet count is above 100 x 10
  <sup>9</sup>/L. Do not start the next cycle until the ANC and platelet count exceed these levels.
 </paragraph>
                        <paragraph>If the ANC is less than 1 x 10
  <sup>9</sup>/L or the platelet count is less than 50 x 10
  <sup>9</sup>/L during any cycle, reduce the Temozolomide dose for the next cycle by 50 mg/m 
  <sup>2</sup>per day. Permanently discontinue Temozolomide in patients who are unable to tolerate a dose of 100 mg/m
  <sup>2 </sup>per day.
 </paragraph>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20240802"/>
                  </section>
               </component>
               <component>
                  <section ID="L381f182c-fb0e-424b-b09b-0ccda9913f01">
                     <id root="312f1b5f-bfc5-7393-e063-6394a90adf08"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Preparation and Administration</title>
                     <text>
                        <paragraph>Temozolomide is a hazardous drug. Follow applicable special handling and disposal procedures.
 
  <sup>1</sup>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Temozolomide capsules</content>
                        </paragraph>
                        <paragraph>Take Temozolomide at the same time each day. Administer Temozolomide consistently with respect to food (fasting vs. nonfasting)
 
  <content styleCode="italics">[see Clinical Pharmacology (
  
   <linkHtml href="#Lc6d8638a-5b86-4146-b74c-0c7e5d5e352e">12.3</linkHtml>)]
 
  </content>. To reduce nausea and vomiting, take Temozolomide on an empty stomach or at bedtime and consider antiemetic therapy prior to and following Temozolomide administration.

 </paragraph>
                        <paragraph>Swallow Temozolomide capsules whole with water. Advise patients not to open, chew, or dissolve the contents of the capsules.
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#Lfc481618-194c-44e0-8d83-04a6e3182934">5.6</linkHtml>)]
 
  </content>
                        </paragraph>
                        <paragraph>If capsules are accidentally opened or damaged, take precautions to avoid inhalation or contact with the skin or mucous membranes. In case of powder contact, wash the affected area with water immediately.</paragraph>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="L25bfbd51-b051-49b4-971d-751f14e45aad">
               <id root="3141e86f-608d-d10e-e063-6394a90a584e"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <list listType="unordered">
                     <item>Temozolomide Capsules, USP for oral administration
   <br/>
	– 100mg: have opaque white bodies with opaque purple caps. The cap is imprinted with “NSP” and the capsule body is imprinted with “100mg” in black ink.
   <br/>
	– 140mg: have opaque white bodies with opaque blue caps. The cap is imprinted with “NSP” and the capsule body is imprinted with “140mg” in black ink.
   <br/>
	– 180mg: have opaque white bodies with opaque orange caps. The cap is imprinted with “NSP” and the capsule body is imprinted with “180mg” in black ink.
   <br/>
	– 250mg: have opaque white bodies with opaque white caps. The cap is imprinted with “NSP” and the capsule body is imprinted with “250mg” in black ink.
  </item>
                  </list>
               </text>
               <effectiveTime value="20250401"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>100-mg, 140-mg, 180-mg, and 250-mg capsules. ( 
     <linkHtml href="#L25bfbd51-b051-49b4-971d-751f14e45aad">3</linkHtml>)
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="L77aedc9a-7d18-4259-9fc3-e0c552b06b0b">
               <id root="312f1b5f-bfc7-7393-e063-6394a90adf08"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Temozolomide is contraindicated in patients with a history of serious hypersensitivity reactions to:</paragraph>
                  <list listType="unordered">
                     <item>temozolomide or any other ingredients in Temozolomide capsules; and</item>
                     <item>dacarbazine, since both temozolomide and dacarbazine are metabolized to the same active metabolite 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide.</item>
                  </list>
                  <paragraph>Reactions to Temozolomide have included anaphylaxis
 
  <content styleCode="italics">[see Adverse Reactions (
  
   <linkHtml href="#Lb3022b22-d81b-43dd-b1d7-9355ba529d84">6.2</linkHtml>)]
 
  </content>.

 </paragraph>
               </text>
               <effectiveTime value="20240804"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>History of serious hypersensitivity to temozolomide or any other ingredients in Temozolomide Capsules and dacarbazine. (
  
     <linkHtml href="#L77aedc9a-7d18-4259-9fc3-e0c552b06b0b">4</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="L6416291b-0c0c-4bde-bed2-f3992e73f21e">
               <id root="3141e939-b7ac-d77c-e063-6394a90a12bd"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20250401"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <content styleCode="underline">Myelosuppression:</content>Monitor absolute neutrophil count (ANC) and platelet count prior to each cycle and during treatment. Geriatric patients and women have a higher risk of developing myelosuppression. ( 
     <linkHtml href="#L2b03d759-1023-43fd-90bb-52951c3e166d">5.1</linkHtml>, 
     <linkHtml href="#L982d77ac-5651-460a-b81e-d82c1b315a4c">8.5</linkHtml>)
    </item>
                           <item>
                              <content styleCode="underline">Hepatotoxicity:</content>Fatal and severe hepatotoxicity have been reported. Perform liver tests at baseline, midway through the first cycle, prior to each subsequent cycle, and approximately 2 to 4 weeks after the last dose of Temozolomide. ( 
     <linkHtml href="#L62e6fbd2-9596-410f-b58c-dd99c18af3fb">5.2</linkHtml>)
    </item>
                           <item>
                              <content styleCode="underline">
                                 <content styleCode="italics">Pneumocystis</content>Pneumonia (PCP): 
     </content>Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. ( 
     <linkHtml href="#L0ea5877a-44fb-4c11-8b4f-e81641c0216d">5.3</linkHtml>)
    </item>
                           <item>
                              <content styleCode="underline">Secondary Malignancies:</content>Myelodysplastic syndrome and secondary malignancies, including myeloid leukemia, have been observed. ( 
     <linkHtml href="#L518de09b-418e-4e71-8164-f9f9e863953a">5.4</linkHtml>)
    </item>
                           <item>
                              <content styleCode="underline">Embryo-Fetal Toxicity:</content>Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception. Advise male patients with pregnant partners or female partners of reproductive potential to use condoms. ( 
     <linkHtml href="#L645662c6-fdf7-4b2b-85e6-1b88efd90758">5.5</linkHtml>, 
     <linkHtml href="#L736f164f-d532-469b-8a9f-5b42d0c02cca">8.1</linkHtml>, 
     <linkHtml href="#L18de6e2b-c749-4acc-9f12-1aec604f698b">8.3</linkHtml>)
    </item>
                           <item>
                              <content styleCode="underline">Exposure to Opened Capsules:</content>Temozolomide capsules should not be opened, chewed, or dissolved but should be swallowed whole with a glass of water. ( 
     <linkHtml href="#Lfc481618-194c-44e0-8d83-04a6e3182934">5.6</linkHtml>)
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="L2b03d759-1023-43fd-90bb-52951c3e166d">
                     <id root="312f1b5f-bfc9-7393-e063-6394a90adf08"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Myelosuppression</title>
                     <text>
                        <paragraph>Myelosuppression, including pancytopenia, leukopenia and anemia, some with fatal outcomes, have occurred with Temozolomide
 
  <content styleCode="italics">[see Adverse Reactions (
  
   <linkHtml href="#Ld66a7d24-e39a-4f17-9258-1da507e1149b">6.1</linkHtml>,
  
   <linkHtml href="#Lb3022b22-d81b-43dd-b1d7-9355ba529d84">6.2</linkHtml>)]
 
  </content>.

 </paragraph>
                        <paragraph>In MK-7365-006, myelosuppression usually occurred during the first few cycles of therapy and was generally not cumulative. The median nadirs occurred at 26 days for platelets (range: 21 to 40 days) and 28 days for neutrophils (range: 1 to 44 days). Approximately 10% of patients required hospitalization, blood transfusion, or discontinuation of therapy due to myelosuppression. Geriatric patients and women have been shown in clinical trials to have a higher risk of developing myelosuppression.</paragraph>
                        <paragraph>Obtain a complete blood count and monitor ANC and platelet counts before initiation of treatment and as clinically indicated during treatment. When TEMOZOLOMIDE is used in combination with radiotherapy, obtain a complete blood count prior to initiation of treatment, weekly during treatment, and as clinically indicated
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#L631abb25-b00d-4d7c-8bd3-52c0d3f941c7">2.1</linkHtml>,
  
   <linkHtml href="#La4f70f90-3a94-40d6-a5d6-e2b7490103eb">2.2</linkHtml>,
  
   <linkHtml href="#Lc2b2d7b3-3bfe-4eae-9279-ee145c4d4a9e">2.3</linkHtml>)]
 
  </content>.

 </paragraph>
                        <paragraph>For severe myelosuppression, withhold TEMOZOLOMIDE and then resume at same or reduced dose, or permanently discontinue, based on occurrence
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#L631abb25-b00d-4d7c-8bd3-52c0d3f941c7">2.1</linkHtml>,
  
   <linkHtml href="#La4f70f90-3a94-40d6-a5d6-e2b7490103eb">2.2</linkHtml>,
  
   <linkHtml href="#Lc2b2d7b3-3bfe-4eae-9279-ee145c4d4a9e">2.3</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20240904"/>
                  </section>
               </component>
               <component>
                  <section ID="L62e6fbd2-9596-410f-b58c-dd99c18af3fb">
                     <id root="312f1b5f-bfca-7393-e063-6394a90adf08"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Hepatotoxicity</title>
                     <text>
                        <paragraph>Fatal and severe hepatotoxicity have been reported in patients receiving Temozolomide. Perform liver tests at baseline, midway through the first cycle, prior to each subsequent cycle, and approximately two to four weeks after the last dose of Temozolomide.</paragraph>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
               <component>
                  <section ID="L0ea5877a-44fb-4c11-8b4f-e81641c0216d">
                     <id root="312f1b5f-bfcb-7393-e063-6394a90adf08"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3

 <content styleCode="italics">Pneumocystis</content>Pneumonia
</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Pneumocystis</content>pneumonia (PCP) has been reported in patients receiving Temozolomide. The risk of PCP is increased in patients receiving steroids or with longer treatment regimens of Temozolomide.

 </paragraph>
                        <paragraph>For patients with newly diagnosed glioblastoma, provide PCP prophylaxis for all patients during the concomitant phase. Continue PCP prophylaxis in patients who experience lymphopenia, until resolution to Grade 1 or less
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#L631abb25-b00d-4d7c-8bd3-52c0d3f941c7">2.1</linkHtml>)]
 
  </content>.

 </paragraph>
                        <paragraph>Monitor all patients receiving Temozolomide for the development of lymphopenia and PCP.</paragraph>
                     </text>
                     <effectiveTime value="20240802"/>
                  </section>
               </component>
               <component>
                  <section ID="L518de09b-418e-4e71-8164-f9f9e863953a">
                     <id root="312f1b5f-bfcc-7393-e063-6394a90adf08"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Secondary Malignancies</title>
                     <text>
                        <paragraph>The incidence of secondary malignancies is increased in patients treated with Temozolomide-containing regimens. Cases of myelodysplastic syndrome and secondary malignancies, including myeloid leukemia, have been observed following Temozolomide administration.</paragraph>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
               <component>
                  <section ID="L645662c6-fdf7-4b2b-85e6-1b88efd90758">
                     <id root="312f1b5f-bfcd-7393-e063-6394a90adf08"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Embryo-Fetal Toxicity</title>
                     <text>
                        <paragraph>Based on findings from animal studies and its mechanism of action, Temozolomide can cause fetal harm when administered to a pregnant woman. Adverse developmental outcomes have been reported in both pregnant patients and pregnant partners of male patients. Oral administration of temozolomide to rats and rabbits during the period of organogenesis resulted in embryolethality and polymalformations at doses less than the maximum human dose based on body surface area.</paragraph>
                        <paragraph>Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with Temozolomide and for 6 months after the last dose. Because of potential risk of genotoxic effects on sperm, advise male patients with female partners of reproductive potential to use condoms during treatment with Temozolomide and for 3 months after the last dose. Advise male patients not to donate semen during treatment with Temozolomide and for 3 months after the last dose
 
  <content styleCode="italics">[see Use in Specific Populations (
  
   <linkHtml href="#L736f164f-d532-469b-8a9f-5b42d0c02cca">8.1</linkHtml>,
  
   <linkHtml href="#L18de6e2b-c749-4acc-9f12-1aec604f698b">8.3</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
               <component>
                  <section ID="Lfc481618-194c-44e0-8d83-04a6e3182934">
                     <id root="312f1b5f-bfce-7393-e063-6394a90adf08"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Exposure to Opened Capsules</title>
                     <text>
                        <paragraph>Advise patients not to open, chew or dissolve the contents of the Temozolomide capsules. Swallow capsules whole with a glass of water. If a capsule becomes damaged, avoid contact of the powder contents with skin or mucous membranes. In case of powder contact, wash affected area with water immediately
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#L381f182c-fb0e-424b-b09b-0ccda9913f01">2.4</linkHtml>)]
 
  </content>. If Temozolomide capsules must be opened or the contents must be dissolved, this should be done by a professional trained in safe handling of hazardous drugs using appropriate equipment and safety procedures.

 </paragraph>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="L27b342f1-6da6-4569-8e3d-05b4a28f049e">
               <id root="3141e6c1-2ebf-00cb-e063-6294a90ae8bc"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in the labeling:</paragraph>
                  <list listType="unordered">
                     <item>Myelosuppression 
   <content styleCode="italics">[see Warnings and Precautions ( 
    <linkHtml href="#L2b03d759-1023-43fd-90bb-52951c3e166d">5.1</linkHtml>)] 
   </content>.
  </item>
                     <item>Hepatotoxicity 
   <content styleCode="italics">[see Warnings and Precautions ( 
    <linkHtml href="#L62e6fbd2-9596-410f-b58c-dd99c18af3fb">5.2</linkHtml>)] 
   </content>.
  </item>
                     <item>
                        <content styleCode="italics">Pneumocystis</content>Pneumonia 
   <content styleCode="italics">[see Warnings and Precautions ( 
    <linkHtml href="#L0ea5877a-44fb-4c11-8b4f-e81641c0216d">5.3</linkHtml>)] 
   </content>.
  </item>
                     <item>Secondary Malignancies 
   <content styleCode="italics">[see Warnings and Precautions ( 
    <linkHtml href="#L518de09b-418e-4e71-8164-f9f9e863953a">5.4</linkHtml>)] 
   </content>.
  </item>
                  </list>
               </text>
               <effectiveTime value="20250401"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>The most common adverse reactions (≥20%) are: alopecia, fatigue, nausea, vomiting, headache, constipation, anorexia, and convulsions. ( 
     <linkHtml href="#Ld66a7d24-e39a-4f17-9258-1da507e1149b">6.1</linkHtml>)
    </item>
                           <item>The most common Grade 3 to 4 hematologic laboratory abnormalities (≥10%) in patients with anaplastic astrocytoma are: decreased lymphocytes, decreased platelets, decreased neutrophils, and decreased leukocytes. ( 
     <linkHtml href="#Ld66a7d24-e39a-4f17-9258-1da507e1149b">6.1</linkHtml>)
    </item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact NextSource Pharma at 1-855-672-2468 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Ld66a7d24-e39a-4f17-9258-1da507e1149b">
                     <id root="3141af0d-88a2-c161-e063-6394a90afd0f"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Newly Diagnosed Glioblastoma</content>
                        </paragraph>
                        <paragraph>The safety of Temozolomide was evaluated in study MK-7365-051 
  <content styleCode="italics">[see Clinical Studies ( 
   <linkHtml href="#L6099d054-a5df-4fe5-a2cf-1df6a0c76d94">14.1</linkHtml>)] 
  </content>.
 </paragraph>
                        <paragraph>Severe or life-threatening adverse reactions occurred in 49% of patients treated with Temozolomide; the most common were fatigue (13%), convulsions (6%), headache (5%), and thrombocytopenia (5%).</paragraph>
                        <paragraph>The most common adverse reactions (20%) in patients treated with Temozolomide were alopecia, fatigue, nausea, anorexia, headache, constipation and vomiting.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 3 </content>summarizes the adverse reactions in MK-7365-051.
 </paragraph>
                        <table width="100%">
                           <caption>TABLE 3: Adverse Reactions (≥10%) in Patients with Newly Diagnosed Glioblastoma </caption>
                           <tfoot>
                              <tr>
                                 <td>NOS = not otherwise specified.</td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">NOTE:</content>Grade 5 (fatal) adverse reactions are included in the Grade ≥3 column.
    </td>
                              </tr>
                              <tr>
                                 <td>*One patient who was randomized to radiation therapy-only arm received radiation therapy and TEMOZOLOMIDE.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td rowspan="3" styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">Adverse Reactions</content>
                                 </td>
                                 <td colspan="4" styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">Concomiotant Use Phase</content>
                                 </td>
                                 <td colspan="2" styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">Maintenance Use Phase</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">Radiation Therapy and Temozolomide N=288*</content>
                                 </td>
                                 <td colspan="2" styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">Radiation Therapy Alone N=285</content>
                                 </td>
                                 <td colspan="2" styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">Temozolomide N=224</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">All Grades (%)</content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">Grade ≥3 (%)</content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">All Grades (%)</content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">Grades ≥3 (%)</content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">All Grades (%)</content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">Grade ≥3 (%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="7" styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">Skin and Subcutaneous Tissue</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Alopecia</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">69</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">0</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">63</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">0</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">55</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Rash</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">19</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">1</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">15</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">0</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">13</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">1</td>
                              </tr>
                              <tr>
                                 <td colspan="7" styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">General</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Fatigue</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">54</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">7</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">49</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">5</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">61</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">9</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Anorexia</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">19</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">1</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">9</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">&lt;1</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">27</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Headache</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">19</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">2</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">17</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">4</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">23</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">4</td>
                              </tr>
                              <tr>
                                 <td colspan="7" styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">Gastrointestinal System</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Nausea</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">36</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">1</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">16</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">&lt;1</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">49</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Vomiting</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">20</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">&lt;1</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">6</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">&lt;1</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">29</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Constipation</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">18</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">1</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">6</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">0</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">22</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Diarrhea</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">6</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">0</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">3</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">0</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">10</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">1</td>
                              </tr>
                              <tr>
                                 <td colspan="7" styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">Central and Peripheral Nervous System</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Convulsions</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">6</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">3</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">7</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">3</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">11</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">3</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Clinically relevant adverse reactions in &lt;10% of patients are presented below:</paragraph>
                        <paragraph>
                           <content styleCode="italics">Central &amp; Peripheral Nervous System:</content>memory impairment, confusion
 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Eye:</content>vision blurred
 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal System:</content>stomatitis, abdominal pain
 </paragraph>
                        <paragraph>
                           <content styleCode="italics">General:</content>weakness, dizziness
 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Immune System:</content>allergic reaction
 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Injury:</content>radiation injury not otherwise specified
 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Musculoskeletal System:</content>arthralgia
 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Platelet, Bleeding, &amp; Clotting:</content>thrombocytopenia
 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Psychiatric:</content>insomnia
 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Respiratory System:</content>coughing, dyspnea
 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Special Senses Other:</content>taste perversion
 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin &amp; Subcutaneous Tissue:</content>dry skin, pruritus, erythema
 </paragraph>
                        <paragraph>When laboratory abnormalities and adverse reactions were combined, Grade 3 or Grade 4 neutrophil abnormalities including neutropenic reactions were observed in 8% of patients, and Grade 3 or Grade 4 platelet abnormalities including thrombocytopenic reactions were observed in 14% of patients.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Newly Diagnosed Anaplastic Astrocytoma</content>
                        </paragraph>
                        <paragraph>The safety of Temozolomide for the adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma was derived from published literature 
  <content styleCode="italics">[see Clinical Studies ( 
   <linkHtml href="#L0370f82d-9b24-4899-b599-2fff7af9ebdc">14.2</linkHtml>)] 
  </content>. The safety of Temozolomide for the adjuvant treatment of patients with newly diagnosed anaplastic astrocytoma was consistent with the known safety profile of Temozolomide.
 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Refractory Anaplastic Astrocytoma</content>
                        </paragraph>
                        <paragraph>The safety of Temozolomide was evaluated in study MK-7365-006 
  <content styleCode="italics">[see Clinical Studies ( 
   <linkHtml href="#L0370f82d-9b24-4899-b599-2fff7af9ebdc">14.2</linkHtml>)] 
  </content>.
 </paragraph>
                        <paragraph>The most common adverse reactions (≥20%) were nausea, vomiting, headache, fatigue, constipation, and convulsions.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Tables 4 </content>and 
  <content styleCode="bold">5 </content>summarize the adverse reactions and hematological laboratory abnormalities in MK-7365-006.
 </paragraph>
                        <table width="100%">
                           <caption>TABLE 4: Adverse Reactions (≥10%) in Patients with Refactory Anaplastic Astrocytoma </caption>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">Adverse Reactions</content>
                                 </td>
                                 <td colspan="2" styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">TEMOZOLOMIDE N=158</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule"/>
                                 <td styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">All Reactions (%)</content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">Grade 3-4 (%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">Gastrointestinal System</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Nausea</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">53</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">10</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Vomiting</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">42</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">6</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Constipation</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">33</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Diarrhea</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">16</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">2</td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">General</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Headache</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">41</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">6</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Fatigue</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">34</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">4</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Asthenia</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">13</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">6</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Fever</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">13</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">2</td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">Central and Peripheral Nervous System</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Convulsions</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">23</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">5</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Hemiparesis</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">18</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">6</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Dizziness</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">12</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Coordination abnormal</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">11</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Amnesia</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">10</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">4</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Insomnia</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">10</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">0</td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">Cardiovascular</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Edema peripheral</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">11</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">1</td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">Resistance Mechanism</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Infection viral</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">11</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">0</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Clinically relevant adverse reactions in &lt;10% of patients are presented below:</paragraph>
                        <paragraph>
                           <content styleCode="italics">Central and Peripheral Nervous System:</content>paresthesia, somnolence, paresis, urinary incontinence, ataxia, dysphasia, convulsions local, gait abnormal, confusion
 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Endocrine:</content>adrenal hypercorticism
 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal System:</content>abdominal pain, anorexia
 </paragraph>
                        <paragraph>
                           <content styleCode="italics">General:</content>back pain
 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolic:</content>weight increase
 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Musculoskeletal System:</content>myalgia
 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Psychiatric:</content>anxiety, depression
 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Reproductive Disorders:</content>breast pain female
 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Respiratory System:</content>upper respiratory tract infection, pharyngitis, sinusitis, coughing
 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin &amp; Appendages:</content>rash, pruritus
 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Urinary System:</content>urinary tract infection, micturition increased frequency
 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Vision:</content>diplopia, vision abnormal 
  <sup>1</sup>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">
                              <sup>1</sup>
                           </content>This term includes blurred vision; visual deficit; vision changes; and vision troubles.
 </paragraph>
                        <table width="100%">
                           <caption> TABLE 5: Grade 3 to 4 Hematologic Laboratory Abnormalities That Worsened from Baseline in Patients with Refractory Anaplastic Astrocytoma</caption>
                           <tfoot>
                              <tr>
                                 <td>* Change from Grade 0 to 2 at baseline to Grade 3 or 4 during treatment.</td>
                              </tr>
                              <tr>
                                 <td>Ŧ Denominator range = 142, 158</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule"/>
                                 <td styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">TEMOZOLOMIDE 
      <sup>*,Ŧ</sup>(%) 
     </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Decreased lymphocytes</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">55</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Decreased platelets</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">19</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Decreased neutrophils</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">14</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Decreased leukocytes</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">11</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Decreased hemoglobin</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">4</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Hematological Toxicities for Advanced Gliomas</content>
                        </paragraph>
                        <paragraph>In clinical trial experience with 110 to 111 females and 169 to 174 males (depending on measurements), females experienced higher rates of Grade 4 neutropenia (ANC &lt; 0.5 x 10
  <sup>9</sup>/L) and thrombocytopenia (&lt; 20 x 10
  <sup>9</sup>/L) than males in the first cycle of therapy (12% vs. 5% and 9% vs. 3%, respectively).
 </paragraph>
                        <paragraph>In the entire safety database for which hematologic data exist (N=932), 7% (4/61) and 10% (6/63) of patients ≤ 70 years experienced Grade 4 neutropenia or thrombocytopenia in the first cycle, respectively. For patients 70 years, 7% (62/871) and 6% (48/879) experienced Grade 4 neutropenia or thrombocytopenia in the first cycle, respectively. Pancytopenia, leukopenia, and anemia also occurred.</paragraph>
                     </text>
                     <effectiveTime value="20240904"/>
                  </section>
               </component>
               <component>
                  <section ID="Lb3022b22-d81b-43dd-b1d7-9355ba529d84">
                     <id root="312f1b5f-bfd1-7393-e063-6394a90adf08"/>
                     <code code="90375-7" codeSystem="2.16.840.1.113883.6.1" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post-approval use of Temozolomide. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to the drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Dermatologic:</content>Toxic epidermal necrolysis and Stevens-Johnson syndrome.

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Immune System</content>: Hypersensitivity reactions, including anaphylaxis. Erythema multiforme, which resolved after discontinuation of Temozolomide and, in some cases, recurred upon rechallenge.

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Hematopoietic</content>: Prolonged pancytopenia, which may result in aplastic anemia and fatal outcomes.

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Hepatobiliary</content>: Fatal and severe hepatotoxicity, elevation of liver enzymes, hyperbilirubinemia, cholestasis, and hepatitis.

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Infections</content>: Serious opportunistic infections, including some cases with fatal outcomes, with bacterial, viral (primary and reactivated), fungal, and protozoan organisms.

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Pulmonary</content>: Interstitial pneumonitis, pneumonitis, alveolitis, and pulmonary fibrosis.

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Endocrine</content>: Diabetes insipidus.

 </paragraph>
                     </text>
                     <effectiveTime value="20240802"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="L0281adfd-e33b-4cf5-9311-00acbaac7642">
               <id root="3141e86f-608e-d10e-e063-6394a90a584e"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20250401"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Lactation: Advise not to breastfeed. ( 
     <linkHtml href="#L9dec09d4-3f2d-4e24-8c04-a67dfd28322e">8.2</linkHtml>)
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="L736f164f-d532-469b-8a9f-5b42d0c02cca">
                     <id root="3141b69e-55e7-cac1-e063-6294a90ae774"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Based on findings from animal studies and its mechanism of action 
  <content styleCode="italics">[see Clinical Pharmacology ( 
   <linkHtml href="#Lfbe44f7a-5c59-461d-98db-acecd570efd7">12.1</linkHtml>)] 
  </content>, Temozolomide can cause fetal harm when administered to a pregnant woman. Available postmarketing reports describe cases of spontaneous abortions and congenital malformations, including polymalformations with central nervous system, facial, cardiac, skeletal, and genitourinary system anomalies with exposure to Temozolomide during pregnancy. These cases report similar adverse developmental outcomes to those observed in animal studies. Administration of Temozolomide to rats and rabbits during the period of organogenesis caused numerous external, internal, and skeletal malformations at doses less than the maximum human dose based on body surface area ( 
  <content styleCode="italics">​see</content>
                           <content styleCode="italics">Data</content>). Advise pregnant women of the potential risk to a fetus.
 </paragraph>
                        <paragraph>In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>Five consecutive days of oral administration of temozolomide at doses of 75 and 150 mg/m 
  <sup>2</sup>(0.38 and 0.75 times the human dose of 200 mg/m
  <sup>2</sup>) in rats and rabbits, respectively, during the period of organogenesis (Gestation Days 8-12) caused numerous malformations of the external and internal organs and skeleton in both species. In rabbits, temozolomide at the 150 mg/m
  <sup>2 </sup>dose (0.75 times the human dose of 200 mg/m
  <sup>2</sup>) caused embryolethality as indicated by increased resorptions.
 </paragraph>
                     </text>
                     <effectiveTime value="20240802"/>
                  </section>
               </component>
               <component>
                  <section ID="L9dec09d4-3f2d-4e24-8c04-a67dfd28322e">
                     <id root="312f1b5f-bfd4-7393-e063-6394a90adf08"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>There are no data on the presence of Temozolomide or its metabolites in human milk, the effects on a breastfed child, or the effects on milk production. Because of the potential for serious adverse reactions, including myelosuppression from temozolomide in the breastfed children, advise women not to breastfeed during treatment with Temozolomide and for 1 week after the last dose.</paragraph>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
               <component>
                  <section ID="L18de6e2b-c749-4acc-9f12-1aec604f698b">
                     <id root="312f1b5f-bfd5-7393-e063-6394a90adf08"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential</title>
                     <text>
                        <paragraph>Temozolomide can cause fetal harm when administered to a pregnant woman
 
  <content styleCode="italics">[see Use in Specific Populations (
  
   <linkHtml href="#L736f164f-d532-469b-8a9f-5b42d0c02cca">8.1</linkHtml>)]
 
  </content>.

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Pregnancy Testing</content>
                        </paragraph>
                        <paragraph>Verify pregnancy status in females of reproductive potential prior to initiating Temozolomide
 
  <content styleCode="italics">[see Use in Specific Populations (
  
   <linkHtml href="#L736f164f-d532-469b-8a9f-5b42d0c02cca">8.1</linkHtml>)]
 
  </content>.

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Contraception</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Females</content>
                        </paragraph>
                        <paragraph>Advise females of reproductive potential to use effective contraception during treatment with Temozolomide and for 6 months after the last dose.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Males</content>
                        </paragraph>
                        <paragraph>Because of the potential for embryofetal toxicity and genotoxic effects on sperm cells, advise male patients with pregnant partners or female partners of reproductive potential to use condoms during treatment with Temozolomide and for 3 months after the last dose
 
  <content styleCode="italics">[see Use in Specific Populations (
  
   <linkHtml href="#L736f164f-d532-469b-8a9f-5b42d0c02cca">8.1</linkHtml>), Nonclinical Toxicology (
  
   <linkHtml href="#L6e377b73-5d9a-471b-bcfd-7a55eb1de9f1">13.1</linkHtml>)]
 
  </content>. 
  <br/>  Advise male patients not to donate semen during treatment with Temozolomide and for 3 months after the last dose.

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Infertility</content>
                        </paragraph>
                        <paragraph>Temozolomide may impair male fertility
 
  <content styleCode="italics">[see Nonclinical Toxicology (
  
   <linkHtml href="#L6e377b73-5d9a-471b-bcfd-7a55eb1de9f1">13.1</linkHtml>)]
 
  </content>. Limited data from male patients show changes in sperm parameters during treatment with Temozolomide; however, no information is available on the duration or reversibility of these changes.

 </paragraph>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
               <component>
                  <section ID="La830080c-4bbc-4826-826f-026e207fd4b9">
                     <id root="312f1b5f-bfd6-7393-e063-6394a90adf08"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness of Temozolomide have not been established in pediatric patients. Safety and effectiveness of Temozolomide capsules were assessed, but not established, in 2 open-label studies in pediatric patients aged 3 to 18 years. In one study, 29 patients with recurrent brain stem glioma and 34 patients with recurrent high-grade astrocytoma were enrolled. In a second study conducted by the Children’s Oncology Group (COG), 122 patients were enrolled, including patients with medulloblastoma/PNET (29), high grade astrocytoma (23), low grade astrocytoma (22), brain stem glioma (16), ependymoma (14), other CNS tumors (9), and non-CNS tumors (9). The adverse reaction profile in pediatric patients was similar to adults.</paragraph>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
               <component>
                  <section ID="L982d77ac-5651-460a-b81e-d82c1b315a4c">
                     <id root="312f1b5f-bfd7-7393-e063-6394a90adf08"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>In MK-7365-051, 15% of patients with newly diagnosed glioblastoma were 65 years and older. This study did not include sufficient numbers of patients aged 65 years and older to determine differences in effectiveness from younger patients. No overall differences in safety were observed between patients ≥65 years and younger patients.</paragraph>
                        <paragraph>The CATNON trial did not include sufficient numbers of patients aged 65 years and older to determine differences in safety or effectiveness when compared to younger patients.</paragraph>
                        <paragraph>In MK-7365-006, 4% of patients with refractory anaplastic astrocytoma were 70 years and older. This study did not include sufficient numbers of patients aged 70 years and older to determine differences in effectiveness from younger patients. Patients 70 years and older had a higher incidence of Grade 4 neutropenia (25%) and Grade 4 thrombocytopenia (20%) in the first cycle of therapy than patients less than 70 years of age
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#L2b03d759-1023-43fd-90bb-52951c3e166d">5.1</linkHtml>), Adverse Reactions (
  
   <linkHtml href="#Ld66a7d24-e39a-4f17-9258-1da507e1149b">6.1</linkHtml>)]
 
  </content>.

 </paragraph>
                        <paragraph>In the entire safety database for which hematologic data exist (N=932), 7% (4/61) and 10% (6/63) of patients &gt;70 years experienced Grade 4 neutropenia or thrombocytopenia in the first cycle, respectively. For patients ≤70 years, 7% (62/871) and 6% (48/879) experienced Grade 4 neutropenia or thrombocytopenia in the first cycle, respectively. Pancytopenia, leukopenia, and anemia also occurred.</paragraph>
                     </text>
                     <effectiveTime value="20240802"/>
                  </section>
               </component>
               <component>
                  <section ID="L50ac6f15-4e7a-4a81-8fb4-497b46cf14e1">
                     <id root="3141b69e-55ea-cac1-e063-6294a90ae774"/>
                     <code code="88828-9" codeSystem="2.16.840.1.113883.6.1" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph>No dosage adjustment is recommended for patients with creatinine clearance (CLcr) of 36 to 130 mL/min/m
  <sup>2</sup>
                           <content styleCode="italics">[see Clinical Pharmacology ( 
   <linkHtml href="#Lc6d8638a-5b86-4146-b74c-0c7e5d5e352e">12.3</linkHtml>)] 
  </content>. The recommended dose of Temozolomide has not been established for patients with severe renal impairment (CLcr &lt; 36 mL/min/m
  <sup>2</sup>) or for patients with end-stage renal disease on dialysis.
 </paragraph>
                     </text>
                     <effectiveTime value="20240802"/>
                  </section>
               </component>
               <component>
                  <section ID="Lf2844828-594d-4f10-8280-e6f62b6e5950">
                     <id root="312f1b5f-bfd9-7393-e063-6394a90adf08"/>
                     <code code="88829-7" codeSystem="2.16.840.1.113883.6.1" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>8.7 Hepatic Impairment</title>
                     <text>
                        <paragraph>No dosage adjustment is recommended for patients with mild to moderate hepatic impairment (Child Pugh class A and B)
 
  <content styleCode="italics">[see Clinical Pharmacology (
  
   <linkHtml href="#Lc6d8638a-5b86-4146-b74c-0c7e5d5e352e">12.3</linkHtml>)]
 
  </content>. The recommended dose of Temozolomide has not been established for patients with severe hepatic impairment (Child-Pugh class C).

 </paragraph>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="L7912af42-779c-454c-ba8f-5b19c326b6ed">
               <id root="3141e86f-608f-d10e-e063-6394a90a584e"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>Dose-limiting toxicity was myelosuppression and was reported with any dose but is expected to be more severe at higher doses. An overdose of 2000 mg per day for 5 days was taken by one patient and the adverse reactions reported were pancytopenia, pyrexia, multi-organ failure, and death. There are reports of patients who have taken more than 5 days of treatment (up to 64 days), with adverse reactions reported including myelosuppression, which in some cases was severe and prolonged, and infections and resulted in death. In the event of an overdose, monitor complete blood count and provide supportive measures as necessary.</paragraph>
               </text>
               <effectiveTime value="20250401"/>
            </section>
         </component>
         <component>
            <section ID="Lece2668c-0e64-4dad-aa58-9b245ae43fcb">
               <id root="3141e40c-56fb-f29d-e063-6294a90a12bb"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Temozolomide Capsules, USP are an alkylating drug. The chemical name of temozolomide, USP is 3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]- 
  <content styleCode="italics">a</content>s-tetrazine-8-carboxamide. The structural formula of temozolomide, USP is:
 </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L903e0c9c-8730-4691-9bba-63965c43df7f"/>
                  </paragraph>
                  <paragraph>The material is a white to light tan/light pink powder with a molecular formula of C 
  <sub>6</sub>H 
  <sub>6</sub>N 
  <sub>6</sub>O 
  <sub>2</sub>and a molecular weight of 194.15. The molecule is stable at acidic pH (&lt;5) and labile at pH &gt;7; hence temozolomide, USP can be administered orally. The prodrug, temozolomide, is rapidly hydrolyzed to the active 5-(3-methyltriazen-1-yl) imidazole-4-carboxamide (MTIC) at neutral and alkaline pH values, with hydrolysis taking place even faster at alkaline pH.
 </paragraph>
                  <paragraph>Temozolomide Capsules, USP:</paragraph>
                  <paragraph>Temozolomide capsules, USP for oral use contain either 100 mg, 140 mg, 180 mg, or 250 mg of temozolomide.</paragraph>
                  <paragraph>The inactive ingredients are as follows:</paragraph>
                  <paragraph>
                     <content styleCode="italics">Temozolomide Capsules 100 mg: </content>lactose anhydrous (61.20 mg), colloidal silicon dioxide (0.80 mg), sodium starch glycolate (9.00 mg), tartaric acid (3.60 mg), and stearic acid (5.40 mg).
 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Temozolomide Capsules 140 mg: </content>lactose anhydrous (85.68 mg), colloidal silicon dioxide (1.12 mg), sodium starch glycolate (12.60 mg), tartaric acid (5.04 mg), and stearic acid (7.56 mg).
 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Temozolomide Capsules 180 mg: </content>lactose anhydrous (110.16 mg), colloidal silicon dioxide (1.44 mg), sodium starch glycolate (16.20 mg), tartaric acid (6.48 mg), and stearic acid (9.72 mg).
 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Temozolomide Capsules 250 mg: </content>lactose anhydrous (153.00 mg), colloidal silicon dioxide (2.00 mg), sodium starch glycolate (22.50 mg), tartaric acid (9.00 mg), and stearic acid (13.50 mg).
 </paragraph>
                  <paragraph>The body of the capsules is made of gelatin and is opaque white with the dosage strength imprinted on them. The cap is also made of gelatin, imprinted with “NSP”, and the colors vary based on the dosage strength. The capsule body and cap are imprinted with pharmaceutical branding ink, which contains shellac, dehydrated alcohol, isopropyl alcohol, butyl alcohol, propylene glycol, strong ammonia solution, black iron oxide, and purified water.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Temozolomide Capsules 100 mg: </content>The purple cap contains FD&amp;C Blue #2, gelatin, iron oxide red, and titanium dioxide.
 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Temozolomide Capsules 140 mg: </content>The blue cap contains FD&amp;C Blue #2, gelatin, and titanium dioxide.
 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Temozolomide Capsules 180 mg: </content>The orange cap contains gelatin, iron oxide red, iron oxide yellow, and titanium dioxide.
 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Temozolomide Capsules 250 mg: </content>The white cap contains gelatin and titanium dioxide.
 </paragraph>
               </text>
               <effectiveTime value="20250401"/>
               <component>
                  <observationMedia ID="L903e0c9c-8730-4691-9bba-63965c43df7f">
                     <text>structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="temozolomide-structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Lcd7f5ab5-7e44-4bb7-b65b-a722e34e389f">
               <id root="3141e86f-6091-d10e-e063-6394a90a584e"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <text/>
               <effectiveTime value="20250401"/>
               <component>
                  <section ID="Lfbe44f7a-5c59-461d-98db-acecd570efd7">
                     <id root="3141ab18-3d83-c0af-e063-6294a90a37d8"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Temozolomide is not directly active but undergoes rapid nonenzymatic conversion at physiologic pH to the reactive compound 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide (MTIC). The cytotoxicity of MTIC is thought to be primarily due to DNA alkylation, mainly at the O
  <sup>6 </sup>and N
  <sup>7 </sup>positions of guanine, which causes DNA double strand breaks and results in programmed cell death.
 </paragraph>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
               <component>
                  <section ID="L51998ad1-d569-4da8-9570-8866f8f68837">
                     <id root="312f1b5f-bfde-7393-e063-6394a90adf08"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Temozolomide exposure-response relationships and the time course of pharmacodynamic response are unknown.</paragraph>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
               <component>
                  <section ID="Lc6d8638a-5b86-4146-b74c-0c7e5d5e352e">
                     <id root="3141af0d-88a9-c161-e063-6394a90afd0f"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>Following a single oral dose of 150 mg/m
  <sup>2</sup>, the mean C 
  <sub>max</sub>value is 7.5 mcg/mL for temozolomide and 282 ng/mL for MTIC. The mean AUC is 23.4 mcg·hr/mL for temozolomide and 864 ng·hr/mL for MTIC.
 </paragraph>
                        <paragraph>Following a single 90-minute intravenous infusion of 150 mg/m 
  <sup>2</sup>, the mean C 
  <sub>max</sub>is 7.3 mcg/mL and 276 ng/mL for MTIC. The mean AUC is 24.6 mcg·hr/mL for temozolomide and 891 ng·hr/mL for MTIC.
 </paragraph>
                        <paragraph>Temozolomide exhibits linear kinetics over the therapeutic dosing range of 75 mg/m 
  <sup>2</sup>/day to 250 mg/m 
  <sup>2</sup>/day.
 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph>The median T 
  <sub>max</sub>is 1 hour.
 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of Food</content>
                        </paragraph>
                        <paragraph>The mean C 
  <sub>max</sub>and AUC decreased by 32% and 9%, respectively, and median T 
  <sub>max</sub>increased by 2-fold (from 1-2.25 hours) when Temozolomide capsules were administered after a modified high-fat breakfast (587 calories comprised of 1 fried egg, 2 strips of bacon, 2 slices of toast, 2 pats of butter, and 8 oz whole milk).
 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>Temozolomide has a mean (CV%) apparent volume of distribution of 0.4 L/kg (13%). The mean percent bound of drug-related total radioactivity is 15%.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>Clearance of temozolomide is approximately 5.5 L/hr/m 
  <sup>2</sup>and the mean elimination half-life is 1.8 hours.
 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism</content>
                        </paragraph>
                        <paragraph>Temozolomide is spontaneously hydrolyzed at physiologic pH to the active species, MTIC and to temozolomide acid metabolite. MTIC is further hydrolyzed to 5-amino-imidazole-4-carboxamide (AIC), which is known to be an intermediate in purine and nucleic acid biosynthesis, and to methylhydrazine, which is believed to be the active alkylating species. Cytochrome P450 enzymes play a minor role in the metabolism of temozolomide and MTIC. Relative to the AUC of temozolomide, the exposure to MTIC and AIC is 2.4% and 23%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>
                        </paragraph>
                        <paragraph>Approximately 38% of the administered temozolomide total radioactive dose is recovered over 7 days: 38% in urine and 0.8% in feces. The majority of the recovered radioactivity in urine is unchanged temozolomide (6%), AIC (12%), temozolomide acid metabolite (2.3%), and unidentified polar metabolite(s) (17%).</paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>No clinically significant differences in the pharmacokinetics of temozolomide were observed based on age (range: 19-78 years), gender, smoking status (smoker vs. non-smoker), creatinine clearance (CLcr) of 36 to 130 mL/min/m
  <sup>2</sup>, or mild to moderate hepatic impairment (Child Pugh class A and B). The pharmacokinetics of temozolomide has not been studied in patients with CLcr &lt; 36 mL/min/m 
  <sup>2</sup>, end-stage renal disease on dialysis, or severe hepatic impairment (Child-Pugh class C).
 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug Interaction Studies</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Clinical Studies and Model-Informed Approaches</content>
                        </paragraph>
                        <paragraph>No clinically significant differences in the pharmacokinetics of temozolomide or MTIC were observed when co-administered with ranitidine.
  <br/>
No clinically significant differences in the clearance of temozolomide or MTIC were predicted when co-administered with the following drugs: valproic acid, dexamethasone, prochlorperazine, phenytoin, carbamazepine, ondansetron, histamine-2-receptor antagonists, or phenobarbital.
 </paragraph>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="L25d5aaf4-1da7-4103-9cb0-581caf9b0c26">
               <id root="3141eec9-4232-f012-e063-6294a90afb47"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <text/>
               <effectiveTime value="20250401"/>
               <component>
                  <section ID="L6e377b73-5d9a-471b-bcfd-7a55eb1de9f1">
                     <id root="3141ca6d-81e2-b2e0-e063-6394a90aa278"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Temozolomide is carcinogenic in rats at doses less than the maximum recommended human dose. Temozolomide induced mammary carcinomas in both males and females at doses 0.13 to 0.63 times the maximum human dose (25 - 125 mg/m
  <sup>2</sup>) when administered orally on 5 consecutive days every 28 days for 6 cycles. Temozolomide also induced fibrosarcomas of the heart, eye, seminal vesicles, salivary glands, abdominal cavity, uterus, and prostate, carcinomas of the seminal vesicles, schwannomas of the heart, optic nerve, and harderian gland, and adenomas of the skin, lung, pituitary, and thyroid at doses 0.5 times the maximum daily dose.
 </paragraph>
                        <paragraph>Mammary tumors were also induced following 3 cycles of temozolomide at the maximum recommended daily dose.
  <br/>
Temozolomide is a mutagen and a clastogen. In a reverse bacterial mutagenesis assay (Ames assay), temozolomide increased revertant frequency in the absence and presence of metabolic activation. Temozolomide was clastogenic in human lymphocytes in the presence and absence of metabolic activation.
 </paragraph>
                        <paragraph>Temozolomide impairs male fertility. Temozolomide caused syncytial cells/immature sperm formation at doses of 50 and 125 mg/m
  <sup>2 </sup>(0.25 and 0.63 times the human dose of 200 mg/m
  <sup>2</sup>) in rats and dogs, respectively, and testicular atrophy in dogs at 125 mg/m
  <sup>2</sup>.
 </paragraph>
                     </text>
                     <effectiveTime value="20240804"/>
                  </section>
               </component>
               <component>
                  <section ID="L89bc5da5-8ec0-4a1b-9c70-168fe382b9b2">
                     <id root="3141ba91-054f-a205-e063-6394a90a124d"/>
                     <code code="34091-9" codeSystem="2.16.840.1.113883.6.1" displayName="ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION"/>
                     <title>13.2 Animal Toxicology and/or Pharmacology</title>
                     <text>
                        <paragraph>Toxicology studies in rats and dogs identified a low incidence of hemorrhage, degeneration, and necrosis of the retina at temozolomide doses equal to or greater than 125 mg/m
  <sup>2 </sup>(0.63 times the human dose of 200 mg/m
  <sup>2</sup>). These changes were most commonly seen at doses where mortality was observed.
 </paragraph>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Lc84ad13c-2d4d-4873-8ecb-3181ef998a41">
               <id root="3141efb5-2a2f-b44a-e063-6294a90ab6aa"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20250401"/>
               <component>
                  <section ID="L6099d054-a5df-4fe5-a2cf-1df6a0c76d94">
                     <id root="3141c765-682f-be65-e063-6394a90a8a3a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Newly Diagnosed Glioblastoma</title>
                     <text>
                        <paragraph>The efficacy of Temozolomide was evaluated in study MK-7365-051 ( 
  <linkHtml href="https://clinicaltrials.gov/ct2/show/record/NCT00006353">NCT00006353</linkHtml>), a randomized (1:1), multicenter, open-label trial. Eligible patients were required to have newly diagnosed glioblastoma. Patients were randomized to receive either radiation therapy alone or concomitant Temozolomide 75 mg/m
  <sup>2 </sup>once daily starting the first day of radiation therapy and continuing until the last day of radiation therapy for 42 days (with a maximum of 49 days), followed by Temozolomide 150 mg/m
  <sup>2 </sup>or 200 mg/m
  <sup>2 </sup>once daily on Days 1 to 5 of each 28-day cycle, starting 4 weeks after the end of radiation therapy and continuing for 6 cycles. In both arms, focal radiation therapy was delivered as 60 Gy/30 fractions and included radiation to the tumor bed or resection site with a 2- to 3-cm margin. PCP prophylaxis was required during the concomitant phase regardless of lymphocyte count and continued until recovery of lymphocyte count to Grade 1 or less. The major efficacy outcome measure was overall survival.
 </paragraph>
                        <paragraph>A total of 573 patients were randomized, 287 to Temozolomide and radiation therapy and 286 to radiation therapy alone. At the time of disease progression, Temozolomide was administered as salvage therapy in 161 patients of the 282 (57%) in the radiation therapy alone arm and 62 patients of the 277 (22%) in the Temozolomide and radiation therapy arm.</paragraph>
                        <paragraph>The addition of concomitant and maintenance Temozolomide to radiation therapy for the treatment of patients with newly diagnosed glioblastoma showed a statistically significant improvement in overall survival compared to radiotherapy alone ( 
  <content styleCode="bold">Figure 1</content>). The hazard ratio (HR) for overall survival was 0.63 (95% CI: 0.52, 0.75) with a log-rank 
  <content styleCode="italics">P</content>&lt;0.0001 in favor of the Temozolomide arm. The median overall survival was 14.6 months in the Temozolomide arm and 12.1 months for radiation therapy alone arm.
 </paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="Lde3639e0-cdd4-4f2e-a78f-fa215969789c"/>
                        </paragraph>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20240804"/>
                     <component>
                        <observationMedia ID="Lde3639e0-cdd4-4f2e-a78f-fa215969789c">
                           <text>figure-1</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="telozolomide-figure-1.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="L0370f82d-9b24-4899-b599-2fff7af9ebdc">
                     <id root="3141d03a-77f0-ed21-e063-6294a90a181e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2 Anaplastic Astrocytoma</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Newly Diagnosed Anaplastic Astrocytoma</content>
                        </paragraph>
                        <paragraph>The efficacy of TEMOZOLOMIDE for the adjuvant treatment of newly diagnosed anaplastic astrocytoma was derived from studies of TEMOZOLOMIDE in the published literature. TEMOZOLOMIDE was evaluated in CATNON ( 
  <linkHtml href="https://clinicaltrials.gov/ct2/show/record/NCT00626990">NCT00626990</linkHtml>), a randomized, open-label, multicenter trial, where the major efficacy outcome measure was overall survival.
 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Refractory Anaplastic Astrocytoma</content>
                        </paragraph>
                        <paragraph>The efficacy of Temozolomide was evaluated in Study MK-7365-006, a single-arm, multicenter trial. Eligible patients had anaplastic astrocytoma at first relapse and a baseline Karnofsky performance status (KPS) of 70 or greater. Patients had previously received radiation therapy and may also have previously received a nitrosourea with or without other chemotherapy. Fifty-four patients had disease progression on prior therapy with both a nitrosourea and procarbazine and their malignancy was considered refractory to chemotherapy (refractory anaplastic astrocytoma population). Temozolomide capsules were given on Days 1 to 5 of each 28-day cycle at a starting dose of 150 mg/m
  <sup>2</sup>/day. If ANC was ≥1.5 x 10
  <sup>9</sup>/L and platelet count was ≥100 x 10
  <sup>9</sup>/L at the nadir and on Day 1 of the next cycle, the Temozolomide dose was increased to 200 mg/m
  <sup>2</sup>/day. The major efficacy outcome measure was progression-free survival at 6 months and the additional efficacy outcome measures were overall survival and overall response rate.
 </paragraph>
                        <paragraph>In the refractory anaplastic astrocytoma population (n=54), the median age was 42 years (range:19 to 76); 65% were male; and 72% had a KPS of &gt;80. Sixty-three percent of patients had surgery other than a biopsy at the time of initial diagnosis. Of those patients undergoing resection, 73% underwent a subtotal resection and 27% underwent a gross total resection. Eighteen percent of patients had surgery at the time of first relapse. The median time from initial diagnosis to first relapse was 13.8 months (range: 4.2 months to 6.3 years).</paragraph>
                        <paragraph>In the refractory anaplastic astrocytoma population, the overall response rate (CR+PR) was 22% (12 of 54 patients) and the complete response rate was 9% (5 of 54 patients). The median duration of all responses was 50 weeks (range: 16 to 114 weeks) and the median duration of complete responses was 64 weeks (range: 52 to 114 weeks). In this population, progression-free survival at 6 months was 45% (95% CI: 31%, 58%) and progression-free survival at 12 months was 29% (95% CI: 16%, 42%). Median progression-free survival was 4.4 months. Overall survival at 6 months was 74% (95% CI: 62%, 86%) and 12-month overall survival was 65% (95% CI: 52%, 78%). Median overall survival was 15.9 months.</paragraph>
                     </text>
                     <effectiveTime value="20240804"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="L94f94d47-8d55-442c-9ac4-6c33961319c3">
               <id root="3141e86f-6092-d10e-e063-6394a90a584e"/>
               <code code="34093-5" codeSystem="2.16.840.1.113883.6.1" displayName="REFERENCES SECTION"/>
               <title>15 REFERENCES</title>
               <text>
                  <paragraph>1. “OSHA Hazardous Drugs.” 
  <content styleCode="italics">OSHA</content>. http://www.osha.gov/hazardous-drugs.
 </paragraph>
               </text>
               <effectiveTime value="20250401"/>
            </section>
         </component>
         <component>
            <section ID="L390cc45e-db57-487d-8af5-ddebe4c7c329">
               <id root="3141eec9-4233-f012-e063-6294a90afb47"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED / STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Temozolomide is a hazardous drug. Follow applicable special handling and disposal procedures. 
  <sup>1</sup>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Temozolomide Capsules, USP</content>
                  </paragraph>
                  <paragraph>Temozolomide Capsules, USP are supplied in sachets containing the following capsule strengths:</paragraph>
                  <paragraph>
                     <content styleCode="italics">Temozolomide Capsules 100 mg: </content>have opaque white bodies with opaque purple caps. The cap is imprinted with “NSP” and the capsule body is imprinted with “100mg” in black ink.
 </paragraph>
                  <paragraph>They are supplied as follows:</paragraph>
                  <paragraph>14-count - NDC 58181-4321-4</paragraph>
                  <paragraph>
                     <content styleCode="italics">Temozolomide Capsules 140 mg: </content>have opaque white bodies with opaque blue caps. The cap is imprinted with “NSP” and the capsule body is imprinted with “140mg” in black ink.
 </paragraph>
                  <paragraph>They are supplied as follows:</paragraph>
                  <paragraph>14-count - NDC 58181-4331-4</paragraph>
                  <paragraph>
                     <content styleCode="italics">Temozolomide Capsules 180 mg: </content>have opaque white bodies with opaque orange caps. The cap is imprinted with “NSP” and the capsule body is imprinted with “180mg” in black ink.
 </paragraph>
                  <paragraph>They are supplied as follows:</paragraph>
                  <paragraph>14-count - NDC 58181-4341-4</paragraph>
                  <paragraph>
                     <content styleCode="italics">Temozolomide Capsules 250 mg: </content>have opaque white bodies with opaque white caps. The cap is imprinted with “NSP” and the capsule body is imprinted with “250mg” in black ink.
 </paragraph>
                  <paragraph>They are supplied as follows:</paragraph>
                  <paragraph>5-count - NDC 58181-4351-4</paragraph>
                  <paragraph>Store Temozolomide Capsules at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature].</paragraph>
               </text>
               <effectiveTime value="20250401"/>
            </section>
         </component>
         <component>
            <section ID="L29bee350-233c-42be-9566-c9d75af21069">
               <id root="3141f2e7-fc89-d04f-e063-6394a90a3b02"/>
               <code code="88436-1" codeSystem="2.16.840.1.113883.6.1" displayName="PATIENT COUNSELING INFORMATION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Patient Information).</paragraph>
                  <paragraph>
                     <content styleCode="underline">Myelosuppression</content>
                  </paragraph>
                  <paragraph>Inform patients that Temozolomide can cause low blood cell counts and the need for frequent monitoring of blood cell counts. Advise patients to contact their healthcare provider immediately for bleeding, fever, or other signs of infection 
  <content styleCode="italics">[see Warnings and Precautions ( 
   <linkHtml href="#L2b03d759-1023-43fd-90bb-52951c3e166d">5.1</linkHtml>)] 
  </content>.
 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Hepatotoxicity</content>
                  </paragraph>
                  <paragraph>Advise patients of the increased risk of hepatotoxicity and to contact their healthcare provider immediately for signs or symptoms of hepatotoxicity. Inform patients that they will have periodic liver enzyme tests during treatment and following the last dose of Temozolomide 
  <content styleCode="italics">[see Warnings and Precautions ( 
   <linkHtml href="#L62e6fbd2-9596-410f-b58c-dd99c18af3fb">5.2</linkHtml>)] 
  </content>.
 </paragraph>
                  <paragraph>
                     <content styleCode="underline">
                        <content styleCode="italics">Pneumocystis </content>Pneumonia 
  </content>
                  </paragraph>
                  <paragraph>Advise patients of the increased risk of Pneumocystis pneumonia and to contact their healthcare provider immediately for new or worsening pulmonary symptoms. Inform patients that prophylaxis for 
  <content styleCode="italics">Pneumocystis</content>pneumonia may be needed 
  <content styleCode="italics">[see Dosage and Administration ( 
   <linkHtml href="#L631abb25-b00d-4d7c-8bd3-52c0d3f941c7">2.1</linkHtml>), Warnings and Precautions ( 
   <linkHtml href="#undefined">5.3</linkHtml>)] 
  </content>.
 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Secondary Malignancies</content>
                  </paragraph>
                  <paragraph>Advise patients of the increased risk of myelodysplastic syndrome and secondary malignancies 
  <content styleCode="italics">[see Warnings and Precautions ( 
   <linkHtml href="#L518de09b-418e-4e71-8164-f9f9e863953a">5.4</linkHtml>)] 
  </content>.
 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Exposure to Opened Capsules</content>
                  </paragraph>
                  <paragraph>Advise patient to not open, chew, or dissolve the capsules. If capsules are accidentally opened or damaged, advise patients to take rigorous precautions with capsule contents to avoid inhalation or contact with the skin or mucous membranes 
  <content styleCode="italics">[see Warnings and Precautions ( 
   <linkHtml href="#Lfc481618-194c-44e0-8d83-04a6e3182934">5.6</linkHtml>)] 
  </content>. In case of powder contact, wash the affected area with water immediately 
  <content styleCode="italics">[see Dosage and Administration ( 
   <linkHtml href="#L381f182c-fb0e-424b-b09b-0ccda9913f01">2.4</linkHtml>)] 
  </content>.
 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Embryo-Fetal Toxicity</content>
                  </paragraph>
                  <paragraph>Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females to inform their healthcare provider of a known or suspected pregnancy 
  <content styleCode="italics">[see Warnings and Precautions ( 
   <linkHtml href="#L645662c6-fdf7-4b2b-85e6-1b88efd90758">5.5</linkHtml>), Use in Specific Populations ( 
   <linkHtml href="#L736f164f-d532-469b-8a9f-5b42d0c02cca">8.1</linkHtml>)] 
  </content>.
  <br/>
Advise females of reproductive potential to use effective contraception during treatment with Temozolomide and for 6 months after the last dose 
  <content styleCode="italics">[see Use in Specific Populations ( 
   <linkHtml href="#L18de6e2b-c749-4acc-9f12-1aec604f698b">8.3</linkHtml>)] 
  </content>.
 </paragraph>
                  <paragraph>Advise male patients with pregnant partners or female partners of reproductive potential to use condoms during treatment with Temozolomide and for 3 months after the last dose 
  <content styleCode="italics">[see Use in Specific Populations ( 
   <linkHtml href="#L18de6e2b-c749-4acc-9f12-1aec604f698b">8.3</linkHtml>), Nonclinical Toxicology ( 
   <linkHtml href="#L6e377b73-5d9a-471b-bcfd-7a55eb1de9f1">13.1</linkHtml>)] 
  </content>.
  <br/>
Advise male patients not to donate semen during treatment with Temozolomide and for 3 months after the last dose 
  <content styleCode="italics">[see Use in Specific Populations ( 
   <linkHtml href="#L18de6e2b-c749-4acc-9f12-1aec604f698b">8.3</linkHtml>), Nonclinical Toxicology ( 
   <linkHtml href="#L6e377b73-5d9a-471b-bcfd-7a55eb1de9f1">13.1</linkHtml>)] 
  </content>.
 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Lactation</content>
                  </paragraph>
                  <paragraph>Advise women not to breastfeed during treatment with Temozolomide and for 1 week after the last dose 
  <content styleCode="italics">[see Use in Specific Populations ( 
   <linkHtml href="#L9dec09d4-3f2d-4e24-8c04-a67dfd28322e">8.2</linkHtml>)] 
  </content>.
 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Infertility</content>
                  </paragraph>
                  <paragraph>Advise males of reproductive potential that Temozolomide may impair fertility 
  <content styleCode="italics">[see Use in Specific Populations ( 
   <linkHtml href="#L18de6e2b-c749-4acc-9f12-1aec604f698b">8.3</linkHtml>), Nonclinical Toxicology ( 
   <linkHtml href="#L6e377b73-5d9a-471b-bcfd-7a55eb1de9f1">13.1</linkHtml>)] 
  </content>.
 </paragraph>
                  <paragraph>Manufactured by:</paragraph>
                  <paragraph>Eirgen Pharma Ltd.</paragraph>
                  <paragraph>Waterford, Ireland</paragraph>
                  <paragraph>Distributed by:</paragraph>
                  <paragraph>NextSource Pharma,</paragraph>
                  <paragraph>Pompano Beach, FL 33069, USA</paragraph>
                  <paragraph>Made in Ireland</paragraph>
                  <paragraph>PC2596
  <br/>
Rev. 08/2024
 </paragraph>
               </text>
               <effectiveTime value="20250401"/>
            </section>
         </component>
         <component>
            <section ID="Lafa9e38d-76d0-43c9-bd54-8ccfe962f3cd">
               <id root="3141efb5-2a30-b44a-e063-6294a90ab6aa"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <title>Patient Information</title>
               <text>
                  <table width="100%">
                     <caption/>
                     <tbody>
                        <tr>
                           <td align="center" colspan="2" styleCode="Botrule Lrule Rrule Toprule">
                              <paragraph>Temozolomide</paragraph>
                              <paragraph>(tem" oh zol' oh mide)</paragraph>
                              <paragraph>Capsules, USP</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Botrule Lrule Rrule Toprule">
                              <content styleCode="bold">What is Temozolomide?</content>
                              <br/>
			Temozolomide is a prescription medicine used to treat adults with certain brain cancer tumors.
     <br/>
			It is not known if Temozolomide is safe and effective in children.
    </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Botrule Lrule Rrule Toprule">
                              <paragraph>
                                 <content styleCode="bold">Do not take TEMOZOLOMIDE if you:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>have had an allergic reaction to temozolomide or any of the other ingredients in TEMOZOLOMIDE. See the end of this leaflet for a list of ingredients in TEMOZOLOMIDE. Symptoms of an allergic reaction with TEMOZOLOMIDE may include: a red itchy rash, or a severe allergic reaction, such as trouble breathing, swelling of the face, throat, or tongue, or severe skin reaction. If you are not sure, ask your healthcare provider.</item>
                                 <item>have had an allergic reaction to dacarbazine (DTIC), another cancer medicine.</item>
                              </list>
                              <paragraph/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Botrule Lrule Rrule Toprule">
                              <paragraph>
                                 <content styleCode="bold">Before taking or receiving TEMOZOLOMIDE, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>have kidney problems</item>
                                 <item>have liver problems</item>
                                 <item>are pregnant or plan to become pregnant. 
       <content styleCode="bold">TEMOZOLOMIDE can harm your unborn baby and cause birth defects.
        <br/>
				﻿Females who can become pregnant:
       </content>
                                    <list listType="unordered">
                                       <item>You should not become pregnant during treatment with TEMOZOLOMIDE.</item>
                                       <item>You should use an effective form of birth control (contraception) during treatment and for 6 months after your last dose of TEMOZOLOMIDE.</item>
                                       <item>Your healthcare provider should do a pregnancy test to make sure that you are not pregnant before you start taking TEMOZOLOMIDE.</item>
                                       <item>Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with TEMOZOLOMIDE.</item>
                                    </list>
                                    <content styleCode="bold">Males with a female partner who is pregnant or who can become pregnant:</content>
                                    <list listType="unordered">
                                       <item>Use a condom for birth control (contraception) during treatment and for 3 months after taking your last dose of TEMOZOLOMIDE.</item>
                                       <item>
                                          <content styleCode="bold">Do not </content>donate semen during treatment and for 3 months after your last dose of TEMOZOLOMIDE.
        </item>
                                    </list>
                                 </item>
                              </list>
                              <list listType="unordered">
                                 <item>are breastfeeding or plan to breastfeed. It is not known if TEMOZOLOMIDE passes into your breast milk. Do not breastfeed during treatment and for 1 week after your last dose of TEMOZOLOMIDE.</item>
                              </list>
                              <paragraph>Tell your doctor about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements.</paragraph>
                              <paragraph>Know the medicines you take. Keep a list of them and show it to your healthcare provider and pharmacist when you get a new medicine.</paragraph>
                              <paragraph/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Botrule Lrule Rrule Toprule">
                              <paragraph>
                                 <content styleCode="bold">How should I take TEMOZOLOMIDE?</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>you may take TEMOZOLOMIDE by mouth as a capsule,</item>
                                 <item>Your healthcare provider will decide the best way for you to take TEMOZOLOMIDE.</item>
                                 <item>If your healthcare provider prescribes TEMOZOLOMIDE capsules for you, take the capsules exactly as prescribed.</item>
                              </list>
			There are 2 common dosing schedules for taking or receiving TEMOZOLOMIDE depending on the type of brain cancer tumor that you have.

			
     <list listType="unordered">
                                 <item>People with certain brain cancer tumors take or receive TEMOZOLOMIDE:
				
       <list listType="unordered">
                                       <item>1 time each day for 42 to 49 days in a row, along with receiving radiation treatment. This is 1 cycle of treatment.
         <br/>
					After this, your healthcare provider may prescribe 6 more cycles of TEMOZOLOMIDE as “maintenance” treatment. For each of these cycles, you take or receive TEMOZOLOMIDE 1 time each day for 5 days in a row and then you stop taking it for the next 23 days. ﻿ 
         <content styleCode="bold">This is a 28-day maintenance treatment cycle.</content>
                                       </item>
                                    </list>
                                 </item>
                              </list>
                              <list listType="unordered">
                                 <item>People with certain other brain cancer tumors take or receive TEMOZOLOMIDE:﻿
				
       <list listType="unordered">
                                       <item>1 time each day for 5 days in a row only, and then stop taking it for the next 23 days. This is 1 cycle of treatment (28 days).</item>
                                       <item>Your healthcare provider will watch your progress on TEMOZOLOMIDE and decide how long you should take it.</item>
                                    </list>
                                 </item>
                              </list>
                              <list listType="unordered">
                                 <item>If your healthcare provider prescribes a treatment regimen that is different from the information in this leaflet, make sure you follow the instructions given to you by your healthcare provider.</item>
                                 <item>Your healthcare provider may change your dose of TEMOZOLOMIDE, or tell you to stop TEMOZOLOMIDE for a short period of time or permanently if you have certain side effects.</item>
                                 <item>Your healthcare provider will decide how many treatment cycles of TEMOZOLOMIDE that you will receive, depending on how you respond to and tolerate treatment.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">TEMOZOLOMIDE capsules:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>Take TEMOZOLOMIDE capsules exactly as your healthcare provider tells you to.</item>
                                 <item>TEMOZOLOMIDE capsules contain a white capsule body with a color cap and the colors vary based on the dosage strength. Your healthcare provider may prescribe more than 1 strength of TEMOZOLOMIDE capsules for you, so it is important that you understand how to take your medicine the right way. Be sure that you understand exactly how many capsules you need to take on each day of your treatment, and what strengths to take. 
       <content styleCode="bold">This may be different whenever you start a new cycle.</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not take more TEMOZOLOMIDE than prescribed.</content>
                                 </item>
                                 <item>Talk to your healthcare provider or pharmacist before taking your dose if you are not sure how much TEMOZOLOMIDE to take. This will help to prevent taking too many TEMOZOLOMIDE and decrease your chances of getting serious side effects.</item>
                                 <item>Take each day's dose of TEMOZOLOMIDE capsules at one time, with a full glass of water.</item>
                                 <item>Take TEMOZOLOMIDE capsules at the same time each day.</item>
                                 <item>Take TEMOZOLOMIDE the same way each time, either with food or without food.</item>
                                 <item>
                                    <content styleCode="bold">Swallow TEMOZOLOMIDE capsules whole with water. Do not </content>open, chew, or dissolve the contents of the capsules.
      </item>
                                 <item>If TEMOZOLOMIDE capsules are accidentally opened or damaged, be careful not to breathe in (inhale) the powder from the capsules or get the powder on your skin or mucous membranes (for example, in your nose or mouth). If contact with any of these areas happens, wash the area with water right away.</item>
                                 <item>To help reduce nausea and vomiting, try to take TEMOZOLOMIDE on an empty stomach or at bedtime. Your healthcare provider may prescribe medicine to help prevent or treat nausea, or other medicines to reduce side effects with TEMOZOLOMIDE.</item>
                                 <item>See your healthcare provider regularly to check your progress. Your healthcare provider will check you for side effects.</item>
                                 <item>If you take more TEMOZOLOMIDE than prescribed, call your healthcare provider or get emergency medical help right away.</item>
                              </list>
                              <paragraph/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Botrule Lrule Rrule Toprule">
                              <paragraph>
                                 <content styleCode="bold">What are the possible side effects of TEMOZOLOMIDE?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">TEMOZOLOMIDE can cause serious side effects, including:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <content styleCode="bold">Decreased blood cell counts. </content>TEMOZOLOMIDE can affect your bone marrow and cause you to have decreased blood cell counts. Decreased white blood cell count, red blood cell count and platelet count are common with TEMOZOLOMIDE but it can also be severe and lead to death. Some people need to be hospitalized or need to receive transfusions to treat their decreased blood cell counts.

				
       <list listType="unordered">
                                       <item>Your healthcare provider will do blood tests regularly to check your blood cell counts before you start and during treatment with TEMOZOLOMIDE.</item>
                                       <item>Your healthcare provider may need to change the dose of TEMOZOLOMIDE or when you get it depending on your blood cell counts.</item>
                                       <item>People who are age 70 or older and women have a higher risk for developing decreased blood cell counts during treatment with TEMOZOLOMIDE.</item>
                                    </list>
                                 </item>
                              </list>
                              <list listType="unordered">
                                 <item>
                                    <content styleCode="bold">Liver problems. Liver problems can happen with TEMOZOLOMIDE and can sometimes be severe and lead to death. </content>Your healthcare provider will do blood tests to check your liver function before you start taking TEMOZOLOMIDE, during treatment, and about 2 to 4 weeks after your last dose of TEMOZOLOMIDE.
      </item>
                                 <item>
                                    <content styleCode="bold">
                                       <content styleCode="italics">Pneumocystis</content>pneumonia (PCP). 
       </content>PCP is an infection that people can get when their immune system is weak. TEMOZOLOMIDE decreases white blood cells, which makes your immune system weaker and can increase your risk of getting PCP.
				
       <list listType="unordered">
                                       <item>People who are taking steroid medicines or who stay on TEMOZOLOMIDE for a longer period of time may have an increased risk of getting PCP infection.</item>
                                       <item>Anyone who takes TEMOZOLOMIDE will be watched carefully by their healthcare provider for low blood cell counts and this infection.</item>
                                       <item>Tell your healthcare provider if you have any of the following signs and symptoms of PCP infection: shortness of breath, or fever, chills, dry cough.</item>
                                    </list>
                                 </item>
                              </list>
                              <list listType="unordered">
                                 <item>
                                    <content styleCode="bold">Secondary Cancers. </content>Blood problems such as myelodysplastic syndrome (MDS) and new cancers (secondary cancers), including a certain kind of leukemia, can happen in people who take TEMOZOLOMIDE. Your healthcare provider will monitor you for this.
      </item>
                              </list>
                              <paragraph>Common side effects of TEMOZOLOMIDE include:</paragraph>
                              <list listType="unordered">
                                 <item>hair loss</item>
                                 <item>feeling tired</item>
                                 <item>nausea and vomiting</item>
                                 <item>headache</item>
                                 <item>constipation</item>
                                 <item>loss of appetite</item>
                                 <item>convulsions</item>
                              </list>
                              <paragraph>TEMOZOLOMIDE can affect fertility in males and may affect your ability to father a child. Talk with your healthcare provider if fertility is a concern for you.</paragraph>
                              <paragraph>Tell your healthcare provider about any side effect that bothers you or that does not go away.</paragraph>
                              <paragraph>These are not all the possible side effects of TEMOZOLOMIDE. For more information, ask your healthcare provider or pharmacist.</paragraph>
                              <paragraph>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph>
                              <paragraph/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Botrule Lrule Rrule Toprule">
                              <paragraph>
                                 <content styleCode="bold">How should I store TEMOZOLOMIDE capsules?</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>Store TEMOZOLOMIDE capsules at room temperature between 68°F to 77°F (20°C to 25°C).</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Keep TEMOZOLOMIDE and all medicines out of the reach of children.</content>
                              </paragraph>
                              <paragraph/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Botrule Lrule Rrule Toprule">
                              <content styleCode="bold">General information about the safe and effective use of TEMOZOLOMIDE.</content>
                              <br/>
			Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use TEMOZOLOMIDE for a condition for which it was not prescribed. Do not give TEMOZOLOMIDE to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about TEMOZOLOMIDE that is written for health professionals.
    </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Botrule Lrule Rrule Toprule">
                              <paragraph>
                                 <content styleCode="bold">What are the ingredients in TEMOZOLOMIDE?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">TEMOZOLOMIDE capsules:</content>
                                 <br/>
                                 <content styleCode="bold">Active ingredient:</content>temozolomide, USP
     </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Inactive ingredients:</content>lactose anhydrous, colloidal silicon dioxide, sodium starch glycolate, tartaric acid, stearic acid.
     </paragraph>
                              <paragraph>The body of the capsules is made of gelatin and is opaque white. The cap is also made of gelatin, and the colors vary based on the dosage strength. The capsule body and cap are imprinted with pharmaceutical branding ink, which contains shellac, dehydrated alcohol, isopropyl alcohol, butyl alcohol, propylene glycol, purified water, strong ammonia, and ferric oxide.</paragraph>
                              <paragraph>TEMOZOLOMIDE 100 mg: The purple cap contains gelatin, titanium dioxide, and iron oxide red, and FD&amp;C Blue #2.
      <br/>
			TEMOZOLOMIDE 140 mg: The blue cap contains gelatin, titanium dioxide, and FD&amp;C Blue #2.
      <br/>
			TEMOZOLOMIDE 180 mg: The orange cap contains gelatin, iron oxide red, iron oxide yellow and titanium dioxide..
      <br/>
			TEMOZOLOMIDE 250 mg: The white cap contains gelatin and titanium dioxide.
      <br/>
                                 <content styleCode="bold">TEMOZOLOMIDE </content>Distributed by: NextSource Pharma, Pompano Beach, FL 33069, USA
      <br/>
			For more information call 1-855-672-2468.
     </paragraph>
                              <paragraph/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <paragraph>This Patient Information has been approved by the U.S. Food and Drug Administration</paragraph>
                           </td>
                           <td>
                              <paragraph>Revised: 08/2024</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph/>
               </text>
               <effectiveTime value="20250401"/>
            </section>
         </component>
         <component>
            <section ID="L100d9c33-46d3-4375-a9e3-3273250ee6a1">
               <id root="3141efb5-2a31-b44a-e063-6294a90ab6aa"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Principal Display Panel - Carton - NDC 58181-4321-4 - 100 mg Capsules - 14 Individual Sachets</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="Lcc932e1a-3ff7-430a-95af-50bf31b58050"/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 58181-4321-4</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">100 mg per capsule</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">​Temozolomide</content>
                  </paragraph>
                  <paragraph>​Capsules, USP</paragraph>
                  <paragraph>
                     <content styleCode="bold">​For Oral Administration</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">​WARNING: Hazardous Drug</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">​Rx Only</content>
                  </paragraph>
                  <paragraph>​THIS PACKAGE CONTAINS </paragraph>
                  <paragraph>14 INDIVIDUAL SACHETS</paragraph>
                  <paragraph>Each Individual Sachet Contains One Capsule Each.</paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">​Temozolomide</content>​
 </paragraph>
                  <paragraph>Capsules, USP</paragraph>
                  <paragraph>
                     <content styleCode="bold">​For Oral Administration</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">​100 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">​Store at 25ºC (77ºF) excursions permitted to 15-30ºC (59-86ºF) [see USP Controlled Room Temperature]</content>
                  </paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">​Each Capsule Contains:</content>​
 </paragraph>
                  <paragraph>100 mg temozolomide.</paragraph>
                  <paragraph>
                     <content styleCode="bold">​Recommended Dosage:</content>
                  </paragraph>
                  <paragraph>See Prescribing Information.</paragraph>
                  <paragraph>
                     <content styleCode="bold">​Read accompanying directions carefully.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">​WARNING: Hazardous Drug.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">​Do not open the capsules. Swallow whole.</content>
                  </paragraph>
                  <paragraph>If a capsule is damaged, avoid contact with your skin, eyes or nose.</paragraph>
                  <paragraph>Distr. By:</paragraph>
                  <paragraph>NextSource Pharma,</paragraph>
                  <paragraph>Pompano Beach,</paragraph>
                  <paragraph>FL 33069, USA</paragraph>
                  <paragraph>N3 58181-43214 2</paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">​100 mg per capsule</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">​Temozolomide</content>
                  </paragraph>
                  <paragraph>Capsules, USP</paragraph>
                  <paragraph>Rev: Jun 24</paragraph>
                  <paragraph>NextSource Pharma</paragraph>
                  <paragraph/>
                  <paragraph>PC 10358181432149</paragraph>
                  <paragraph>S/N</paragraph>
                  <paragraph>LOT</paragraph>
                  <paragraph>EXP</paragraph>
                  <paragraph/>
                  <paragraph>PC2582</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L2653be00-b1cd-4826-a8fa-0f5b6473faba"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Temozolomide Capsules, USP</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">100 mg</content>
                  </paragraph>
                  <paragraph>PC2607</paragraph>
                  <paragraph>Distr. By: NextSource Pharma,
  <br/>
Pompano Beach, FL 33069, USA
 </paragraph>
                  <paragraph>
                     <content styleCode="bold">WARNING: Hazardous Drug</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Read accompanying directions carefully</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">
                        <content styleCode="bold">1 capsule</content>
                     </content>
                  </paragraph>
                  <paragraph>For oral use</paragraph>
                  <paragraph>LOT</paragraph>
                  <paragraph>EXP</paragraph>
                  <paragraph>N3 58181-43214 2</paragraph>
               </text>
               <effectiveTime value="20250401"/>
               <component>
                  <observationMedia ID="Lcc932e1a-3ff7-430a-95af-50bf31b58050">
                     <text>carton-100mg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="carton-100-mg.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L2653be00-b1cd-4826-a8fa-0f5b6473faba">
                     <text>sachet-100mg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="sachet-100-mg.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="L0fa5159a-f135-4e04-8589-bd46429692af">
               <id root="3141f5d7-9883-cc16-e063-6394a90a1413"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Principal Display Panel - Carton - NDC 58181-4331-4 - 140 mg Capsules - 14 Individual Sachets</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="Ld728abe5-8676-44aa-a92c-c592f54aa256"/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 58181-4331-4</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">140 mg per capsule</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">​Temozolomide</content>
                  </paragraph>
                  <paragraph>​Capsules, USP</paragraph>
                  <paragraph>
                     <content styleCode="bold">​For Oral Administration</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">​WARNING: Hazardous Drug</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">​Rx Only</content>
                  </paragraph>
                  <paragraph>​THIS PACKAGE CONTAINS </paragraph>
                  <paragraph>14 INDIVIDUAL SACHETS</paragraph>
                  <paragraph>Each Individual Sachet Contains One Capsule Each.</paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">​Temozolomide</content>​
 </paragraph>
                  <paragraph>Capsules, USP</paragraph>
                  <paragraph>
                     <content styleCode="bold">​For Oral Administration</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">​140 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">​Store at 25ºC (77ºF) excursions permitted to 15-30ºC (59-86ºF) [see USP Controlled Room Temperature]</content>
                  </paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">​Each Capsule Contains:</content>​
 </paragraph>
                  <paragraph>140 mg temozolomide.</paragraph>
                  <paragraph>
                     <content styleCode="bold">​Recommended Dosage:</content>
                  </paragraph>
                  <paragraph>See Prescribing Information.</paragraph>
                  <paragraph>
                     <content styleCode="bold">​Read accompanying directions carefully.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">​WARNING: Hazardous Drug.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">​Do not open the capsules. Swallow whole.</content>
                  </paragraph>
                  <paragraph>If a capsule is damaged, avoid contact with your skin, eyes or nose.</paragraph>
                  <paragraph>Distr. By:</paragraph>
                  <paragraph>NextSource Pharma,</paragraph>
                  <paragraph>Pompano Beach,</paragraph>
                  <paragraph>FL 33069, USA</paragraph>
                  <paragraph>N3 58181-43314 9</paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">​140 mg per capsule</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">​Temozolomide</content>
                  </paragraph>
                  <paragraph>Capsules, USP</paragraph>
                  <paragraph>Rev: Jun 24</paragraph>
                  <paragraph>NextSource Pharma</paragraph>
                  <paragraph/>
                  <paragraph>PC 10358181433146</paragraph>
                  <paragraph>S/N</paragraph>
                  <paragraph>LOT</paragraph>
                  <paragraph>EXP</paragraph>
                  <paragraph/>
                  <paragraph>PC2583</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L841e0b73-23ff-4135-94cb-556c7d05d057"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Temozolomide Capsules, USP</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">140 mg</content>
                  </paragraph>
                  <paragraph>Distr. by: NextSource Pharma,
  <br/>
Pompano Beach, FL 33069, USA
 </paragraph>
                  <paragraph>
                     <content styleCode="bold">WARNING: Hazardous Drug</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Read accompanying directions carefully</content>
                  </paragraph>
                  <paragraph>PC2608</paragraph>
                  <paragraph>
                     <content styleCode="italics">
                        <content styleCode="bold">1 capsule</content>
                     </content>
                  </paragraph>
                  <paragraph>For oral use</paragraph>
                  <paragraph>LOT</paragraph>
                  <paragraph>EXP</paragraph>
                  <paragraph>N3 58181-43314 9</paragraph>
               </text>
               <effectiveTime value="20250401"/>
               <component>
                  <observationMedia ID="Ld728abe5-8676-44aa-a92c-c592f54aa256">
                     <text>carton-140mg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="carton-140-mg.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L841e0b73-23ff-4135-94cb-556c7d05d057">
                     <text>sachet-140mg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="sachet-140-mg.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="L9d97199a-2e27-43db-af7d-0868cef6923f">
               <id root="3141f663-e4cb-ad95-e063-6394a90a6d9b"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Principal Display Panel - Carton - NDC 58181-4341-4 - 180 mg Capsules - 14 Individual Sachets</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="Lde7cbfdb-7a2d-4dca-bb8e-53cd0a005b51"/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 58181-4341-4</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">180 mg per capsule</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">​Temozolomide</content>
                  </paragraph>
                  <paragraph>​Capsules, USP</paragraph>
                  <paragraph>
                     <content styleCode="bold">​For Oral Administration</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">​WARNING: Hazardous Drug</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">​Rx Only</content>
                  </paragraph>
                  <paragraph>​THIS PACKAGE CONTAINS </paragraph>
                  <paragraph>14 INDIVIDUAL SACHETS</paragraph>
                  <paragraph>Each Individual Sachet Contains One Capsule Each.</paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">​Temozolomide</content>​
 </paragraph>
                  <paragraph>Capsules, USP</paragraph>
                  <paragraph>
                     <content styleCode="bold">​For Oral Administration</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">​180 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">​Store at 25ºC (77ºF) excursions permitted to 15-30ºC (59-86ºF) [see USP Controlled Room Temperature]</content>
                  </paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">​Each Capsule Contains:</content>​
 </paragraph>
                  <paragraph>180 mg temozolomide.</paragraph>
                  <paragraph>
                     <content styleCode="bold">​Recommended Dosage:</content>
                  </paragraph>
                  <paragraph>See Prescribing Information.</paragraph>
                  <paragraph>
                     <content styleCode="bold">​Read accompanying directions carefully.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">​WARNING: Hazardous Drug.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">​Do not open the capsules. Swallow whole.</content>
                  </paragraph>
                  <paragraph>If a capsule is damaged, avoid contact with your skin, eyes or nose.</paragraph>
                  <paragraph>Distr. By:</paragraph>
                  <paragraph>NextSource Pharma,</paragraph>
                  <paragraph>Pompano Beach,</paragraph>
                  <paragraph>FL 33069, USA</paragraph>
                  <paragraph>N3 58181-43414 6</paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">​180 mg per capsule</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">​Temozolomide</content>
                  </paragraph>
                  <paragraph>Capsules, USP</paragraph>
                  <paragraph>Rev: Jun 24</paragraph>
                  <paragraph>NextSource Pharma</paragraph>
                  <paragraph/>
                  <paragraph>PC 10358181434143</paragraph>
                  <paragraph>S/N</paragraph>
                  <paragraph>LOT</paragraph>
                  <paragraph>EXP</paragraph>
                  <paragraph/>
                  <paragraph>PC2584</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L1ab0423e-fe98-4ff6-b008-cd6955a1e8a8"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Temozolomide Capsules, USP</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">180 mg</content>
                  </paragraph>
                  <paragraph>Distr. By: NextSource Pharma,
  <br/>
Pompano Beach, FL 33069, USA
 </paragraph>
                  <paragraph>PC2609</paragraph>
                  <paragraph>
                     <content styleCode="bold">WARNING: Hazardous Drug</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Read accompanying directions carefully</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">1 capsule</content>
                     </content>
                  </paragraph>
                  <paragraph>For oral use</paragraph>
                  <paragraph>LOT</paragraph>
                  <paragraph>EXP</paragraph>
                  <paragraph>N3 58181-43414 6</paragraph>
               </text>
               <effectiveTime value="20250401"/>
               <component>
                  <observationMedia ID="Lde7cbfdb-7a2d-4dca-bb8e-53cd0a005b51">
                     <text>carton-180mg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="carton-180-mg.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L1ab0423e-fe98-4ff6-b008-cd6955a1e8a8">
                     <text>sachet-180mg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="sachet-180-mg.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="L69e67654-a0df-4d16-84e2-855806b97fd4">
               <id root="3141f701-9035-0bb0-e063-6294a90a8d4e"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Principal Display Panel - Carton - NDC 58181-4351-4 - 250 mg Capsules - 5 Individual Sachets</title>
               <text>
                  <paragraph>
                     <renderMultiMedia referencedObject="L60db50fa-e9fd-4b9b-8663-5fdeef120f56"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 58181-4351-4</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">250 mg per capsule</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">​Temozolomide</content>
                  </paragraph>
                  <paragraph>​Capsules, USP</paragraph>
                  <paragraph>
                     <content styleCode="bold">​For Oral Administration</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">​WARNING: Hazardous Drug</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">​Rx Only</content>
                  </paragraph>
                  <paragraph>​THIS PACKAGE CONTAINS </paragraph>
                  <paragraph>5 INDIVIDUAL SACHETS</paragraph>
                  <paragraph>Each Individual Sachet Contains One Capsule Each.</paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">​Temozolomide</content>​
 </paragraph>
                  <paragraph>Capsules, USP</paragraph>
                  <paragraph>
                     <content styleCode="bold">​For Oral Administration</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">​250 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">​Store at 25ºC (77ºF) excursions permitted to 15-30ºC (59-86ºF) [see USP Controlled Room Temperature]</content>
                  </paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">​Each Capsule Contains:</content>​
 </paragraph>
                  <paragraph>250 mg temozolomide.</paragraph>
                  <paragraph>
                     <content styleCode="bold">​Recommended Dosage:</content>
                  </paragraph>
                  <paragraph>See Prescribing Information.</paragraph>
                  <paragraph>
                     <content styleCode="bold">​Read accompanying directions carefully.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">​WARNING: Hazardous Drug.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">​Do not open the capsules. Swallow whole.</content>
                  </paragraph>
                  <paragraph>If a capsule is damaged, avoid contact with your skin, eyes or nose.</paragraph>
                  <paragraph>Distr. By:</paragraph>
                  <paragraph>NextSource Pharma,</paragraph>
                  <paragraph>Pompano Beach,</paragraph>
                  <paragraph>FL 33069, USA</paragraph>
                  <paragraph>N3 58181-43514 3</paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">​250 mg per capsule</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">​Temozolomide</content>
                  </paragraph>
                  <paragraph>Capsules, USP</paragraph>
                  <paragraph>Rev: Jun 24</paragraph>
                  <paragraph>NextSource Pharma</paragraph>
                  <paragraph/>
                  <paragraph>PC 10358181435140</paragraph>
                  <paragraph>S/N</paragraph>
                  <paragraph>LOT</paragraph>
                  <paragraph>EXP</paragraph>
                  <paragraph/>
                  <paragraph>PC2579</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="Leddaf2c4-2444-42ce-8d7c-7ea44ff9c607"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Temozolomide Capsules, USP</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">250 mg</content>
                  </paragraph>
                  <paragraph>Distr. By: NextSource Pharma,
  <br/>
Pompano Beach, FL 33069, USA
 </paragraph>
                  <paragraph>PC2610</paragraph>
                  <paragraph>
                     <content styleCode="bold">WARNING: Hazardous Drug</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Read accompanying directions carefully</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">
                        <content styleCode="bold">1 capsule</content>
                     </content>
                  </paragraph>
                  <paragraph>For oral use</paragraph>
                  <paragraph>LOT</paragraph>
                  <paragraph>EXP</paragraph>
                  <paragraph>N3 58181-43514 3</paragraph>
               </text>
               <effectiveTime value="20250401"/>
               <component>
                  <observationMedia ID="L60db50fa-e9fd-4b9b-8663-5fdeef120f56">
                     <text>carton-250mg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="carton-250-mg.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="Leddaf2c4-2444-42ce-8d7c-7ea44ff9c607">
                     <text>sachet-250mg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="sachet-250-mg.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>